

Addition of docetaxel, zoledronic acid, or both to first-line prostate cancer (STAMPEDE): survival results from an a platform randomised controlled trial

Lancet, The

387, 1163-1177

DOI: [10.1016/s0140-6736\(15\)01037-5](https://doi.org/10.1016/s0140-6736(15)01037-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Central European Journal of Urology, 2016, 69, 131-8.	0.2	14
2	What's new in prostate cancer research?. Canadian Urological Association Journal, 2016, 10, 127.	0.3	0
3	Chemotherapy research for metastatic prostate cancer. Canadian Urological Association Journal, 2016, 10, 140.	0.3	3
4	Androgen deprivation therapy as backbone therapy in the management of prostate cancer. OncoTargets and Therapy, 2016, Volume 9, 7263-7274.	1.0	41
5	Androgen receptor axis-targeted agents. Canadian Urological Association Journal, 2016, 10, 146.	0.3	1
6	Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 264-270.	1.2	1
7	Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer. Anti-Cancer Drugs, 2016, 27, 695-701.	0.7	3
8	Febrile Neutropenia Rates in Men Treated with Docetaxel Chemotherapy for Metastatic Hormone-sensitive Prostate Cancer. Clinical Oncology, 2016, 28, 612.	0.6	7
9	Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?. Prostate Cancer and Prostatic Diseases, 2016, 19, 380-384.	2.0	40
10	Relevance of randomised controlled trials in oncology. Lancet Oncology, The, 2016, 17, e560-e567.	5.1	74
11	The role of chemotherapy and new targeted agents in the management of primary prostate cancer. Journal of Clinical Urology, 2016, 9, 30-37.	0.1	2
12	â€œCollaboration Through Communicationâ€ The Young Urology Researchers Organisation (<sc>YURO</sc>). BJU International, 2016, 118, 6-7.	1.3	4
13	Chemohormonal Therapy for Hormone-Sensitive Prostate Cancer. Cancer Journal (Sudbury, Mass), 2016, 22, 322-325.	1.0	2
14	Evolving Use of Androgen Deprivation Therapy in Prostate Cancer Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 663-665.	2.3	4
15	Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2016, 2, 463-464.	1.6	1
17	Developments in urologic oncology â€œOncoForumâ€ The best of 2015. Actas UrolÃ³gicas EspaÃ±olas (English Edition), 2016, 40, 361-369.	0.2	4
18	High Risk of Neutropenia for Hormone-naïve Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice. Clinical Oncology, 2016, 28, 611.	0.6	8
19	Continuous versus intermittent docetaxel for metastatic castration resistant prostate cancer. Critical Reviews in Oncology/Hematology, 2016, 102, 118-124.	2.0	7

#	ARTICLE	IF	CITATIONS
20	Defining new standards of care for men with prostate cancer. <i>Lancet, The</i> , 2016, 387, 1135-1137.	6.3	1
21	Avances en uro-oncología «OncoForum»: lo mejor de 2015. <i>Actas Urológicas Españolas</i> , 2016, 40, 361-369.	0.3	8
22	The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. <i>World Journal of Urology</i> , 2016, 34, 1601-1609.	1.2	37
23	Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. <i>Investigational New Drugs</i> , 2016, 34, 474-480.	1.2	11
24	Immediate androgen deprivation: for all or for some?. <i>Lancet Oncology, The</i> , 2016, 17, 683-684.	5.1	3
25	Predictors of duration of abiraterone acetate in men with castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 398-405.	2.0	12
26	Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients. <i>Scandinavian Journal of Urology</i> , 2016, 50, 352-359.	0.6	7
27	Castration-resistant Prostate Cancer: Preservation of Quality of Life and Well-being. <i>European Urology Focus</i> , 2016, 2, 472-475.	1.6	1
29	The Use of Biomarkers to Manage Men with Metastatic Prostate Cancer: One Day, But Not Yet. <i>European Urology Focus</i> , 2016, 2, 467-468.	1.6	0
30	Therapeutic management of bone metastasis in prostate cancer: an update. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1199-1211.	1.1	9
31	Prostate cancer perspectives after charted: Optimizing treatment sequence. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 107, 119-127.	2.0	6
32	PARP inhibitors and stratified treatment of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 1213-1215.	1.1	6
33	Castration-resistant prostate cancer: Why should urologists care?. <i>Urologia Colombiana</i> , 2016, 25, 198-200.	0.0	0
34	Epigenetic modulators as therapeutic targets in prostate cancer. <i>Clinical Epigenetics</i> , 2016, 8, 98.	1.8	68
35	STAMPEDE trial and patients with non-metastatic prostate cancer. <i>Lancet, The</i> , 2016, 388, 234-235.	6.3	3
36	STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply. <i>Lancet, The</i> , 2016, 388, 235-236.	6.3	6
37	Response to “High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice”, by Tanguay et al.. <i>Clinical Oncology</i> , 2016, 28, 666-667.	0.6	4
38	Chemotherapy for metastatic castration-sensitive prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 726-733.	0.5	14

#	ARTICLE	IF	CITATIONS
39	Utility of novel androgen receptor therapies in the real world: A nuanced approach. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 340-347.	0.8	2
40	Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 360-369.	0.5	62
41	Biennial report on genitourinary cancers. <i>European Journal of Cancer</i> , 2016, 66, 125-130.	1.3	1
42	Loss of SLCO1B3 drives taxane resistance in prostate cancer. <i>British Journal of Cancer</i> , 2016, 115, 674-681.	2.9	51
43	HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. <i>Lancet Oncology, The</i> , 2016, 17, 1435-1444.	5.1	107
44	Highlights in Genitourinary (Prostate) Cancer. <i>JAMA Oncology</i> , 2016, 2, 1257.	3.4	0
45	The oncologists' unmet clinical needs for imaging in advanced prostate cancer. <i>Clinical and Translational Imaging</i> , 2016, 4, 423-431.	1.1	2
46	Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2810-2811.	0.8	3
47	The very-high-risk prostate cancer: a contemporary update. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 340-348.	2.0	29
48	Ongoing Clinical Trials in Prostate Cancer: The STAMPEDE Trial. <i>Oncology Research and Treatment</i> , 2016, 39, 464-467.	0.8	1
49	Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer. <i>Oncologist</i> , 2016, 21, 1427-1435.	1.9	60
50	Ten Years on the Juggernaut Keeps on Rolling: Comments on the STAMPEDE Trial from the Front Line. <i>Clinical Oncology</i> , 2016, 28, 547-549.	0.6	2
51	Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever. <i>European Urology</i> , 2016, 70, 707-708.	0.9	16
52	The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. <i>ESMO Open</i> , 2016, 1, e000066.	2.0	17
53	Advances in the management of castration resistant prostate cancer. <i>BMJ, The</i> , 2016, 355, i4405.	3.0	71
54	Androgen Deprivation Therapy for Advanced Prostate Cancer: Can Evolution Be Accelerated?. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 701-703.	2.3	4
55	Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2016, 10s1, CMO.S34535.	0.6	34
56	Models and impact of patient and public involvement in studies carried out by the Medical Research Council Clinical Trials Unit at University College London: findings from ten case studies. <i>Trials</i> , 2016, 17, 376.	0.7	51

#	ARTICLE	IF	CITATIONS
57	The evolving role of chemotherapy in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 262-265.	0.5	1
58	An Update on Triptorelin: Current Thinking on Androgen Deprivation Therapy for Prostate Cancer. <i>Advances in Therapy</i> , 2016, 33, 1072-1093.	1.3	40
59	Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 6259-6264.	3.3	127
60	Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2835-2842.	0.8	213
61	A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 25-33.	3.4	22
62	Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?. <i>European Urology</i> , 2016, 70, 722-723.	0.9	4
63	Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer. <i>Medical Oncology</i> , 2016, 33, 77.	1.2	11
64	Changing standard of care in hormone-sensitive disease. <i>Nature Reviews Urology</i> , 2016, 13, 61-61.	1.9	0
65	Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 44, 61-73.	3.4	56
66	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology</i> , The, 2016, 17, 243-256.	5.1	361
67	A Randomised Comparison Evaluating Changes in Bone Mineral Density in Advanced Prostate Cancer: Luteinising Hormone-releasing Hormone Agonists Versus Transdermal Oestradiol. <i>European Urology</i> , 2016, 69, 1016-1025.	0.9	26
68	Local Treatment of the Prostate in Metastatic Prostate Cancer: Need to Change the Concept?. <i>European Urology</i> , 2017, 72, 20-21.	0.9	0
69	METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. <i>European Urology</i> , 2017, 71, 81-92.	0.9	230
70	Clinical Applications of Molecular Imaging in the Management of Prostate Cancer. <i>PET Clinics</i> , 2017, 12, 185-192.	1.5	12
71	Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. <i>Prostate</i> , 2017, 77, 639-646.	1.2	23
72	The evolving role of chemotherapy in prostate cancer. <i>Future Oncology</i> , 2017, 13, 1091-1095.	1.1	14
73	Cardiovascular toxicities of systemic treatments of prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 230-243.	1.9	15
74	Finding the right dose of rifampicin, and the right dose of optimism. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 2-3.	4.6	5

#	ARTICLE	IF	CITATIONS
75	Management of Prostate Cancer. , 2017, , .		5
76	Bone-Targeted Therapies in Prostate Cancer. , 2017, , 343-356.		1
77	ProCAID: a phase I clinical trial to combine the AKT inhibitor AZD5363 with docetaxel and prednisolone chemotherapy for metastatic castration resistant prostate cancer. Investigational New Drugs, 2017, 35, 599-607.	1.2	41
78	Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care " Cancer Care Ontario Clinical Practice Guideline. Clinical Oncology, 2017, 29, 348-355.	0.6	33
80	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. European Urology, 2017, 72, 521-531.	0.9	174
81	Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. Journal of Oncology Practice, 2017, 13, 9-18.	2.5	14
82	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene, 2017, 36, 3417-3427.	2.6	68
83	Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance. Molecular Cancer Research, 2017, 15, 457-466.	1.5	10
84	Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer and Prostatic Diseases, 2017, 20, 221-227.	2.0	70
85	Mechanisms of Therapeutic Resistance in Prostate Cancer. Current Oncology Reports, 2017, 19, 13.	1.8	103
86	La quimioterapia no deber�a todav�a ser considerada en los pacientes con c�ncer de pr�stata metast�sico hormonosensible. Actas Urol�gicas Espa�olas, 2017, 41, 347-351.	0.3	0
89	Influence of the location and number of metastases in the survival of metastatic prostatic cancer patients. Actas Urol�gicas Espa�olas (English Edition), 2017, 41, 226-233.	0.2	5
90	Denosumab treatment in the management of patients with advanced prostate cancer: clinical evidence and experience. Therapeutic Advances in Urology, 2017, 9, 81-88.	0.9	27
91	Cytoreductive Prostatectomy for Metastatic Prostate Cancer: First Lessons Learned From the Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Trial. Urology, 2017, 106, 146-152.	0.5	42
92	Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis. Supportive Care in Cancer, 2017, 25, 2871-2879.	1.0	6
93	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. European Urology, 2017, 72, 509-518.	0.9	26
94	Cellular determinants and microenvironmental regulation of prostate cancer metastasis. Seminars in Cancer Biology, 2017, 44, 83-97.	4.3	54
95	The intensive care medicine research agenda on septic shock. Intensive Care Medicine, 2017, 43, 1294-1305.	3.9	61

#	ARTICLE	IF	CITATIONS
96	Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. <i>Cancer Treatment Reviews</i> , 2017, 57, 16-27.	3.4	156
97	The role of adaptive trial designs in drug development. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 727-736.	1.3	14
98	Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e801-e807.	0.9	16
99	Advances in urology 2015â€“2016. <i>Journal of Clinical Urology</i> , 2017, 10, 39-48.	0.1	0
100	Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from â€œcastration-resistantâ€™ prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 1692-1694.	0.6	4
101	Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint. <i>Statistics in Medicine</i> , 2017, 36, 3137-3153.	0.8	13
103	Treat All Known Disease. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 494.	0.4	0
104	Molecular biomarkers to guide precision medicine in localized prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 791-804.	1.5	20
105	Adaptive Clinical Trials: Advantages and Disadvantages of Various Adaptive Design Elements. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	63
106	Therapies for castrationâ€“resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines. <i>International Journal of Urology</i> , 2017, 24, 566-572.	0.5	22
107	Stereotactic Body Radiotherapy. <i>Medical Radiology</i> , 2017, , 323-395.	0.0	0
108	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	13.9	1,588
109	Docetaxel in prostate cancer: a familiar face as the new standard in a hormone-sensitive setting. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 307-318.	1.4	49
110	Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 319-333.	1.4	18
111	A three-drug co-delivery system based on reduction-sensitive polymeric prodrug to effectively reverse multi-drug resistance. <i>Chemical Research in Chinese Universities</i> , 2017, 33, 484-491.	1.3	5
113	Prolactin receptor targeting in breast and prostate cancers: New insights into an old challenge. , 2017, 179, 111-126.		57
114	Factors Associated With Survival Following Radium-223 Treatment for Metastatic Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e969-e975.	0.9	41
115	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	13.9	1,315

#	ARTICLE	IF	CITATIONS
116	Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity. <i>Journal of Hematology and Oncology</i> , 2017, 10, 118.	6.9	20
117	Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. <i>Cancer</i> , 2017, 123, 2489-2496.	2.0	17
118	The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies. <i>Cancer</i> , 2017, 123, 1912-1924.	2.0	52
119	Docetaxel chemotherapy in metastatic castration-resistant prostate cancer: cost of care in Medicare and commercial populations. <i>Current Medical Research and Opinion</i> , 2017, 33, 1133-1139.	0.9	5
120	A Pilot Trial Evaluating Zoledronic Acid Induced Changes in [18F]FMAU-Positron Emission Tomography Imaging of Bone Metastases in Prostate Cancer. <i>Molecular Imaging and Biology</i> , 2017, 19, 810-816.	1.3	3
121	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. <i>JAMA Oncology</i> , 2017, 3, e170231.	3.4	9
123	Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand. <i>Prostate International</i> , 2017, 5, 1-7.	1.2	2
124	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). <i>Urology</i> , 2017, 104, 150-159.	0.5	29
126	Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. <i>European Journal of Cancer</i> , 2017, 72, 20-27.	1.3	34
127	Improved outcomes and precision medicine come within reach. <i>Nature Reviews Urology</i> , 2017, 14, 71-72.	1.9	4
128	Impact of treatment on progression to castration-resistance, metastases, and death in men with localized high-grade prostate cancer. <i>Cancer Medicine</i> , 2017, 6, 163-172.	1.3	16
129	Zoledronic Acid in First-Line Treatment of Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 6-8.	0.4	3
130	Postoperative Radiation After Radical Prostatectomy. <i>Seminars in Radiation Oncology</i> , 2017, 27, 50-66.	1.0	4
132	Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform. <i>Clinical Oncology</i> , 2017, 29, 778-786.	0.6	13
133	Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?. <i>Urologic Clinics of North America</i> , 2017, 44, 611-621.	0.8	46
134	Cost-effectiveness comparison between neoadjuvant chemohormonal therapy and extended pelvic lymph node dissection in high-risk prostate cancer patients treated with radical prostatectomy: a multi-institutional analysis. <i>Medical Oncology</i> , 2017, 34, 190.	1.2	13
136	The unidirectional hypoxia-activated prodrug OCT1002 inhibits growth and vascular development in castrate-resistant prostate tumors. <i>Prostate</i> , 2017, 77, 1539-1547.	1.2	9
137	Evaluation and management of skeletal disease in cancer care. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 120, 217-226.	2.0	12

#	ARTICLE	IF	CITATIONS
138	Clinical relevance of androgen receptor alterations in prostate cancer. <i>Endocrine Connections</i> , 2017, 6, R146-R161.	0.8	87
139	Progressive MS trials: Lessons learned. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1583-1592.	1.4	17
140	Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach. <i>European Urology Supplements</i> , 2017, 16, 309-315.	0.1	10
141	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. <i>European Urology</i> , 2017, 72, 899-907.	0.9	23
142	Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world. <i>BJU International</i> , 2017, 120, 751-754.	1.3	7
143	Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer. <i>Future Oncology</i> , 2017, 13, 1911-1913.	1.1	3
144	Testing many treatments within a single protocol over 10 years at MRC Clinical Trials Unit at UCL: Multi-arm, multi-stage platform, umbrella and basket protocols. <i>Clinical Trials</i> , 2017, 14, 451-461.	0.7	59
145	Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 6802-6811.	3.2	69
146	Castration-naïve metastatic prostate cancer: reshaping old paradigms. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 879-881.	1.1	3
147	The Role of Hormonal Treatment in Prostate Cancer. , 2017, , 333-349.		0
148	Impact of five-tiered Gleason grade groups on prognostic prediction in clinical stage T3 prostate cancer undergoing high-dose-rate brachytherapy. <i>Prostate</i> , 2017, 77, 1520-1527.	1.2	6
149	STAMPEDE, LATITUDE and Fernand Labrie's legacy. <i>Nature Reviews Urology</i> , 2017, 14, 588-590.	1.9	5
151	Role of collaboration between urologists and medical oncologists in the advanced prostate cancer space. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 665-669.	0.8	0
152	Cáncer de próstata y cáncer de testículo. <i>Medicine</i> , 2017, 12, 1966-1979.	0.0	0
153	The role of bone-targeted therapies for prostate cancer in 2017. <i>Current Opinion in Supportive and Palliative Care</i> , 2017, 11, 216-224.	0.5	4
154	The evolution of chemotherapy for the treatment of prostate cancer. <i>Annals of Oncology</i> , 2017, 28, 2658-2669.	0.6	57
155	Influencia de la localización y del número de metástasis en la supervivencia de los pacientes con cáncer de próstata metastásico. <i>Actas Urológicas Españolas</i> , 2017, 41, 226-233.	0.3	7
157	Improved Outcomes in Men with Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 388-390.	13.9	6

#	ARTICLE	IF	CITATIONS
158	Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer. <i>Scientific Reports</i> , 2017, 7, 5901.	1.6	49
159	“Thursday’s child has far to go” interpreting subgroups and the STAMPEDE trial. <i>Annals of Oncology</i> , 2017, 28, 2327-2330.	0.6	15
160	Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1234-1242.	0.4	35
161	Accurate p -values for adaptive designs with binary endpoints. <i>Statistics in Medicine</i> , 2017, 36, 2643-2655.	0.8	6
162	The biology of prostate cancer metastases. <i>Current Opinion in Urology</i> , 2017, 27, 542-546.	0.9	8
163	Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer. <i>Anti-Cancer Drugs</i> , 2017, 28, 120-126.	0.7	10
164	Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study. <i>Prostate</i> , 2017, 77, 1356-1365.	1.2	7
165	Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer. <i>Urology</i> , 2017, 109, 1-2.	0.5	0
166	Radiation therapy to the primary in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 580-586.	0.9	5
167	Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 559-565.	0.9	10
168	Chemotherapy for oligometastatic prostate cancer. <i>Current Opinion in Urology</i> , 2017, 27, 553-558.	0.9	4
170	Diagnostic characteristics of lethal prostate cancer. <i>European Journal of Cancer</i> , 2017, 84, 18-26.	1.3	31
171	Chemotherapy in the Management of Prostate Cancer. , 2017, , 351-365.		0
172	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2017, 109, 6-18.	0.5	15
173	A new standard-of-care for advanced-stage disease. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 592-593.	12.5	4
175	Androgen deprivation therapy for the treatment of prostate cancer: a focus on pharmacokinetics. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 1265-1273.	1.5	19
176	Castration-Resistant Prostate Cancer. <i>Urologic Clinics of North America</i> , 2017, 44, 647-655.	0.8	2
177	Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy. <i>BJU International</i> , 2017, 120, 815-821.	1.3	53

#	ARTICLE	IF	CITATIONS
178	A Case of Locally Advanced Castration-resistant Prostate Cancer With Remarkable Response to Nivolumab. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e881-e884.	0.9	7
179	The Diagnosis and Treatment of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 2532.	3.8	959
180	Dose considerations for anti-cancer drugs in metastatic prostate cancer. <i>Prostate</i> , 2017, 77, 1199-1204.	1.2	5
181	Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. <i>Cancer Cell</i> , 2017, 32, 6-8.	7.7	12
182	ABCB1 Mediates Cabazitaxelâ€“Docetaxel Cross-Resistance in Advanced Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2257-2266.	1.9	49
184	Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. <i>International Journal of Clinical Oncology</i> , 2017, 22, 1087-1093.	1.0	16
186	Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. <i>Clinical Oncology</i> , 2017, 29, e174-e175.	0.6	1
187	Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 809-819.	1.3	3
188	Prostate-Specific Membrane Antigen PET Before Aggressive Local Therapy to the Sternum. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 494-495.	0.4	0
189	Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?. <i>JAMA Oncology</i> , 2017, 3, 11.	3.4	4
190	Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy. <i>JAMA Oncology</i> , 2017, 3, 13.	3.4	5
191	Prostate cancer: Developing novel approaches to castrationâ€“sensitive disease. <i>Cancer</i> , 2017, 123, 29-42.	2.0	8
192	Lymph nodeâ€“positive prostate cancerâ€“From middle child to the new frontier. <i>Cancer</i> , 2017, 123, 387-389.	2.0	0
193	Prognostic outlier genes for enhanced prostate cancer treatment. <i>Future Oncology</i> , 2017, 13, 249-261.	1.1	5
194	Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 415-424.	1.7	7
196	Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?. <i>World Journal of Urology</i> , 2017, 35, 567-577.	1.2	23
197	Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e115-e118.	0.9	6
198	Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered. <i>JAMA Oncology</i> , 2017, 3, 68.	3.4	33

#	ARTICLE	IF	CITATIONS
199	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2017, 71, 630-642.	0.9	1,215
200	A phase III multicenter, randomized, controlled study of combined androgen blockade with versus without zoledronic acid in prostate cancer patients with metastatic bone disease: results of the ZAPCA trial. <i>International Journal of Clinical Oncology</i> , 2017, 22, 166-173.	1.0	45
201	High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR ν 7 Expression and Androgen-Independent Cell Growth. <i>Prostate</i> , 2017, 77, 82-93.	1.2	21
202	Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins. <i>Future Oncology</i> , 2017, 13, 369-379.	1.1	9
203	Early use of chemotherapy in metastatic prostate cancer. <i>Cancer Treatment Reviews</i> , 2017, 55, 218-224.	3.4	19
204	Targeting Hypoxic Prostate Tumors Using the Novel Hypoxia-Activated Prodrug OCT1002 Inhibits Expression of Genes Associated with Malignant Progression. <i>Clinical Cancer Research</i> , 2017, 23, 1797-1808.	3.2	25
205	Beyond Just Androgen Deprivation Therapy: Novel Therapies Combined With Radiation. <i>Seminars in Radiation Oncology</i> , 2017, 27, 87-93.	1.0	2
206	Do we need new trials for the abiraterone, enzalutamide and cabazitaxel in metastatic castrate-resistant prostate cancer for confirmation of treatment indications?. <i>World Journal of Urology</i> , 2017, 35, 479-480.	1.2	0
207	A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer. <i>Urology</i> , 2017, 102, 164-172.	0.5	52
208	The role of GATA2 in lethal prostate cancer aggressiveness. <i>Nature Reviews Urology</i> , 2017, 14, 38-48.	1.9	71
209	Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature. <i>Cancer Treatment Reviews</i> , 2017, 55, 211-217.	3.4	20
210	The optimal treatment of metastatic hormone-naïve prostate cancer: abiraterone acetate or docetaxel?. <i>Future Oncology</i> , 2017, 13, 2785-2790.	1.1	5
211	Bisphosphonates for advanced prostate cancer. <i>The Cochrane Library</i> , 2017, 2017, CD006250.	1.5	33
212	Managing patients with metastatic prostate cancer: who takes the lead?. <i>Trends in Urology & Men's Health</i> , 2017, 8, 25-30.	0.2	0
213	Addition of Docetaxel and/or Zoledronic Acid to Standard of Care for Hormone-naïve Prostate Cancer: A Cost-effectiveness Analysis. <i>Tumori</i> , 2017, 103, 380-386.	0.6	12
214	Treatment of Castration-naïve Metastatic Prostate Cancer. <i>European Urology Focus</i> , 2017, 3, 518-521.	1.6	2
216	Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. <i>ESMO Open</i> , 2017, 2, e000272.	2.0	2
217	Diagnosis and Treatment of Prostate Cancer: What Americans Can Learn From International Oncologists. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 344-357.	1.8	3

#	ARTICLE	IF	CITATIONS
219	Docetaxel-Loaded Nanoparticles Assembled from β -Cyclodextrin/Calixarene Giant Surfactants: Physicochemical Properties and Cytotoxic Effect in Prostate Cancer and Glioblastoma Cells. <i>Frontiers in Pharmacology</i> , 2017, 8, 249.	1.6	37
220	Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. <i>Cancers</i> , 2017, 9, 13.	1.7	40
221	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017, 9, 67.	1.7	83
222	The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1512.	1.8	7
223	First brazilian consensus of advanced prostate cancer: recommendations for clinical practice. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2017, 43, 407-415.	0.7	5
224	Current concepts in bone metastasis, contemporary therapeutic strategies and ongoing clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 108.	3.5	97
226	Uncommon case of pericardial effusion. <i>Italian Journal of Medicine</i> , 2017, 11, 331.	0.2	0
227	Circulating Tumor Cells in Genitourinary Malignancies: An Evolving Path to Precision Medicine. <i>Frontiers in Oncology</i> , 2017, 7, 6.	1.3	10
228	Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2017, 15, 349-354.	0.3	11
229	Astaxanthin Inhibits PC-3 Xenograft Prostate Tumor Growth in Nude Mice. <i>Marine Drugs</i> , 2017, 15, 66.	2.2	39
230	Decipher Postprostatectomy: Is It Ready for Clinical Use?. <i>Journal of Clinical Oncology</i> , 2017, 35, 1976-1977.	0.8	5
231	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3189-3197.	0.8	251
232	Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m ²) and the Currently Approved Dose (25 mg/m ²) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA. <i>Journal of Clinical Oncology</i> , 2017, 35, 3198-3206.	0.8	218
233	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	0.8	54
234	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 3181-3188.	0.8	73
235	Treatment of metastatic prostate cancer after STAMPEDE. <i>Translational Andrology and Urology</i> , 2017, 6, 315-316.	0.6	3
238	Molecular Targeted Therapies of Prostate Cancer. <i>Molecular Pathology Library</i> , 2018, , 523-546.	0.1	1
239	Burden of Metastatic Castrate Naïve Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHARTED and GETUG-AFU15 Studies. <i>European Urology</i> , 2018, 73, 847-855.	0.9	174

#	ARTICLE	IF	CITATIONS
240	Seven-month prostate-specific antigen (PSA) is prognostic in patients with prostate cancer initially diagnosed with distant metastases. <i>Medical Oncology</i> , 2018, 35, 46.	1.2	3
242	Does docetaxel prolong survival of patients with non-metastatic castration-resistant prostate cancer?. <i>Prostate</i> , 2018, 78, 498-505.	1.2	8
243	What is the optimal systemic treatment of men with metastatic, hormone-naïve prostate cancer? A STOPCAP systematic review and network meta-analysis. <i>Annals of Oncology</i> , 2018, 29, 1249-1257.	0.6	62
244	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	0.6	196
245	Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road. <i>European Urology</i> , 2018, 73, 877-878.	0.9	2
246	Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer. <i>International Journal of Cancer</i> , 2018, 143, 645-656.	2.3	33
247	The impact of time to metastasis on overall survival in patients with prostate cancer. <i>World Journal of Urology</i> , 2018, 36, 1039-1046.	1.2	27
248	Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. <i>Cancer</i> , 2018, 124, 1921-1928.	2.0	12
249	Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. <i>Current Medical Research and Opinion</i> , 2018, 34, 903-910.	0.9	18
250	Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 507-509.	0.9	2
251	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018, 74, 146-154.	0.9	72
252	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>European Urology</i> , 2018, 74, 283-291.	0.9	82
253	Repurposing of FDA-approved Therapeutics to Identify Novel Radiosensitisers in Hypoxic Prostate Cancer. <i>Clinical Oncology</i> , 2018, 30, 195-196.	0.6	1
255	Weekly versus 3-weekly cabazitaxel for the treatment of castration-resistant prostate cancer: A randomised phase II trial (ConCab). <i>European Journal of Cancer</i> , 2018, 97, 33-40.	1.3	10
256	Sequencing treatment for metastatic prostate cancer. <i>Trends in Urology & Men's Health</i> , 2018, 9, 11-15.	0.2	1
258	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	9.4	182
259	Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 347-352.	0.7	18
261	Outcome of Patients with Node-positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Definitive Surgery or Radiotherapy. <i>Clinical Oncology</i> , 2018, 30, 196-197.	0.6	0

#	ARTICLE	IF	CITATIONS
262	Cost considerations for systemic therapy for patients with advanced genitourinary malignancies. <i>Cancer</i> , 2018, 124, 2897-2905.	2.0	6
263	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 312.e9-312.e15.	0.8	23
265	Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 33-37.	0.3	0
266	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 475-486.	1.3	83
267	Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer – a phase III study (PRINCE). <i>BJU International</i> , 2018, 122, 774-782.	1.3	10
268	Emerging Therapies in Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2018, 20, 46.	1.8	22
270	Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 73, 870-876.	0.9	44
271	Pharmacokinetic/pharmacodynamic drug evaluation of enzalutamide for treating prostate cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 361-369.	1.5	5
272	Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer. <i>British Journal of Cancer</i> , 2018, 118, 802-812.	2.9	12
273	Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2018, 121, 871-879.	1.3	23
274	Metastatic burden in newly diagnosed hormone-naïve metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 158.e13-158.e20.	0.8	27
275	Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 645-657.	13.9	386
276	When and how to use carboplatin in metastatic castration-resistant prostate cancer?. <i>European Journal of Cancer</i> , 2018, 92, 96-99.	1.3	2
277	Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review. <i>Future Oncology</i> , 2018, 14, 431-442.	1.1	14
278	Testosterone Suppression with Luteinizing Hormone-Releasing Hormone (LHRH) Agonists in Patients Receiving Radiotherapy for Prostate Cancer. <i>Pharmacotherapy</i> , 2018, 38, 327-333.	1.2	8
279	Cancer Treatment and Bone Health. <i>Calcified Tissue International</i> , 2018, 102, 251-264.	1.5	60
280	Neoadjuvant and adjuvant treatment in high-risk prostate cancer. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 425-438.	1.3	17
281	Current treatment strategies for advanced prostate cancer. <i>International Journal of Urology</i> , 2018, 25, 220-231.	0.5	164

#	ARTICLE	IF	CITATIONS
282	A randomised phase II trial of docetaxel versus docetaxel plus carboplatin in patients with castration-resistant prostate cancer who have progressed after response to prior docetaxel chemotherapy: The RECARDO trial. <i>European Journal of Cancer</i> , 2018, 90, 1-9.	1.3	20
283	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 306-318.	2.0	21
284	Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. <i>Cancer</i> , 2018, 124, 1383-1390.	2.0	6
285	Testosterone Diminishes Cabazitaxel Efficacy and Intratumoral Accumulation in a Prostate Cancer Xenograft Model. <i>EBioMedicine</i> , 2018, 27, 182-186.	2.7	11
286	A Prospective Audit of Intermittent Anti-Androgen versus Pituitary Blockade Suggests a Bipolar Androgen Type Strategy May Be Safe in Untreated Prostate Cancer. <i>Urologia Internationalis</i> , 2018, 100, 172-180.	0.6	2
287	Effect of Single-agent Daily Prednisone on Outcomes and Toxicities in Metastatic Castration-resistant Prostate Cancer: Pooled Analysis of Prospective Studies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e277-e287.	0.9	4
288	Prostate Cancer. <i>Medical Clinics of North America</i> , 2018, 102, 215-229.	1.1	12
289	Predicting therapy response and resistance in metastatic prostate cancer with circulating tumor DNA. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 380-384.	0.8	13
290	CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 155-163.	1.5	51
292	Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naïve prostate cancer (LATITUDE): an international, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 194-206.	5.1	126
293	Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer. <i>Prostate</i> , 2018, 78, 308-317.	1.2	48
294	Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. <i>European Urology</i> , 2018, 73, 521-523.	0.9	4
295	Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 130-134.	0.9	15
296	Castration is a prerequisite for the inhibitory effect of metronomic chemotherapy on the growth of experimental castration-resistant prostate cancer. <i>Acta Oncologica</i> , 2018, 57, 895-901.	0.8	0
297	Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer: A population-based analysis of 2 national cohorts. <i>Cancer</i> , 2018, 124, 2931-2938.	2.0	58
298	Uro-oncology 2018: new horizons, new treatment options, improved patient outcomes. <i>Memo - Magazine of European Medical Oncology</i> , 2018, 11, 3-4.	0.3	0
299	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. <i>Cancer Treatment Reviews</i> , 2018, 68, 25-37.	3.4	37
301	Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). <i>Prostate</i> , 2018, 78, 889-895.	1.2	111

#	ARTICLE	IF	CITATIONS
302	Bone Metastases in Prostate Cancer. , 2018, , 323-343.		0
303	Metastatic Prostate Cancer. New England Journal of Medicine, 2018, 378, 1653-1654.	13.9	56
304	The case for "successfully"™ treating hormone naïve metastatic prostate cancer. Annals of Oncology, 2018, 29, 1084-1086.	0.6	0
305	Inhibition of the Wnt/β2-Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. Cancer Research, 2018, 78, 3147-3162.	0.4	116
306	PARP inhibitors for homologous recombination-deficient prostate cancer. Expert Opinion on Emerging Drugs, 2018, 23, 123-133.	1.0	24
307	Prognostic Value of [18 F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 406-410.	0.4	11
308	First Results from the ADRRAD Trial " Combination Androgen Deprivation Therapy (ADT), Whole Pelvis Radiotherapy (WPRT) and Radium 223 in Recently Diagnosed Metastatic Hormone Sensitive Prostate Cancer (MHSPCa). Clinical Oncology, 2018, 30, 196.	0.6	2
309	Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor" Targeted Agents. Clinical Genitourinary Cancer, 2018, 16, e777-e784.	0.9	20
310	Androgen Deprivation Fortified. International Journal of Radiation Oncology Biology Physics, 2018, 100, 1098.	0.4	0
311	Prostate Cancer: Improving the Flow of Research. Radiology, 2018, 287, 5-9.	3.6	2
312	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. Medical Oncology, 2018, 35, 56.	1.2	4
313	Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions. Current Opinion in Oncology, 2018, 30, 159-164.	1.1	3
314	Acute myositis. Anti-Cancer Drugs, 2018, 29, 477-481.	0.7	12
315	Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer. European Urology, 2018, 73, 856-858.	0.9	1
316	Therapeutic Patterns and Barriers to the Treatment of Advanced Prostate Cancer: A Survey of Academic and Community Urologists in the United States. Urology Practice, 2018, 5, 15-23.	0.2	0
317	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. European Urology Focus, 2018, 4, 369-375.	1.6	17
318	Peri-prostatic Fat Volume Measurement as a Predictive Tool for Castration Resistance in Advanced Prostate Cancer. European Urology Focus, 2018, 4, 858-866.	1.6	22
319	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	0.9	488

#	ARTICLE	IF	CITATIONS
320	Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. <i>Annals of Oncology</i> , 2018, 29, 215-222.	0.6	86
321	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial. <i>European Urology</i> , 2018, 73, 696-703.	0.9	45
322	Comparison of Surgery and Radiation as Local Treatments in the Risk of Locoregional Complications in Men Subsequently Dying From Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e201-e210.	0.9	1
323	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e233-e242.	0.9	8
324	Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2018, 73, 834-844.	0.9	86
325	Drug development for noncastrate prostate cancer in a changed therapeutic landscape. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 168-182.	12.5	7
326	Antiandrogen withdrawal syndrome (AAWS) in the treatment of patients with prostate cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, R1-R9.	1.6	13
327	<sc>STAMPEDE</sc>â€”ing towards androgen biosynthesis inhibition for treatment of highâ€”risk hormoneâ€”naïve prostate cancer: changing the <sc>LATITUDE</sc>. <i>BJU International</i> , 2018, 121, 9-11.	1.3	6
328	Realâ€”world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer. <i>BJU International</i> , 2018, 121, 268-274.	1.3	21
329	Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. <i>Scandinavian Journal of Urology</i> , 2018, 52, 1-7.	0.6	9
330	Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 85-89.	0.9	34
331	Preliminary results on response assessment using 68Ga-HBED-CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 602-612.	3.3	107
332	Expanding the use of abiraterone in prostate cancer: Is earlier always better?. <i>Cancer Biology and Therapy</i> , 2018, 19, 97-100.	1.5	1
333	Consensus statements on the management of metastatic prostate cancer from the Hong Kong Urological Association and Hong Kong Society of Uroâ€”Oncology. <i>BJU International</i> , 2018, 121, 703-715.	1.3	8
334	Bone-Targeted Therapies in Cancer-Induced Bone Disease. <i>Calcified Tissue International</i> , 2018, 102, 227-250.	1.5	80
335	Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard. <i>European Urology</i> , 2018, 73, 316-321.	0.9	31
336	SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017). <i>Clinical and Translational Oncology</i> , 2018, 20, 57-68.	1.2	17
337	Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers. <i>European Urology</i> , 2018, 73, 845-846.	0.9	4

#	ARTICLE	IF	CITATIONS
338	Assembling the Puzzle of Advanced Prostate Cancer: Lessons from GETUG-AFU 15. <i>European Urology</i> , 2018, 73, 704-705.	0.9	2
339	Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!. <i>European Urology</i> , 2018, 73, 147-148.	0.9	8
340	Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?. <i>Journal of Clinical Oncology</i> , 2018, 36, 937-941.	0.8	7
342	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	0.8	75
343	Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al. <i>Journal of Clinical Oncology</i> , 2018, 36, 2352-2353.	0.8	0
344	Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy: Treatment Patterns From the PROXIMA Prospective Registry. <i>Journal of Global Oncology</i> , 2018, 4, 1-12.	0.5	11
345	Recent trends in the management of advanced prostate cancer. <i>F1000Research</i> , 2018, 7, 1513.	0.8	69
346	Metastatic Castration-Sensitive Prostate Cancer: Optimizing Patient Selection and Treatment. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 363-371.	1.8	27
347	Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2350-2350.	0.8	7
348	Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Global Oncology</i> , 2018, 4, 1-9.	0.5	8
349	Japanese Expert Panel Meeting on the Management of Prostate Cancer with Bone Metastases. <i>Oncology and Therapy</i> , 2018, 6, 157-171.	1.0	1
350	Balancing Outcomes: Focusing on Value in Treatment of Prostate Cancer. <i>Journal of Oncology Practice</i> , 2018, 14, 588-590.	2.5	0
351	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1088-1095.	0.8	72
352	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1521-1539.	0.8	51
353	Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. <i>Asian Journal of Andrology</i> , 2018, 20, 215.	0.8	14
354	First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?. <i>Journal of Clinical Oncology</i> , 2018, 36, 1060-1061.	0.8	12
355	Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: ASCO Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2018, 14, 319-322.	2.5	4
356	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHARTED Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1080-1087.	0.8	702

#	ARTICLE	IF	CITATIONS
357	Chemotherapy and radiation for prostate cancer. <i>Translational Andrology and Urology</i> , 2018, 7, 390-398.	0.6	11
358	Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy. <i>Therapeutic Advances in Urology</i> , 2018, 10, 365-376.	0.9	2
359	Pulmonary lymphangitic carcinomatosis with ground-glass opacities as presentation of prostate cancer. <i>Respirology Case Reports</i> , 2018, 6, e00347.	0.3	6
360	The Current Role of Osteoclast Inhibitors in Patients with Prostate Cancer. <i>Advances in Urology</i> , 2018, 2018, 1-9.	0.6	9
361	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	2.6	19
363	The Hormonal Strategy in Castration-Sensitive Metastatic Prostate Cancer: Should it be Redefined in 2018?. <i>Journal of Clinical Case Reports</i> , 2018, 8, .	0.0	0
364	Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base. <i>European Urology Oncology</i> , 2018, 1, 459-460.	2.6	0
365	Das metastasierte Prostatakarzinom - trotz aller Fortschritte eine Herausforderung. <i>Karger Kompass Onkologie</i> , 2018, 5, 146-147.	0.0	0
366	Management of nonmetastatic castration-resistant prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 366-371.	0.5	1
367	Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>Advances in Therapy</i> , 2018, 35, 2186-2200.	1.3	7
368	Management of bone and metabolic effects of androgen deprivation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 704-712.	0.8	10
369	Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7353-7368.	1.0	58
370	Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2341-2347.	0.9	11
371	The effect of additional chemotherapy on high-risk prostate cancer: a systematic review and meta-analysis. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 9061-9070.	1.0	3
372	Isoalantolactone induces apoptosis through ROS-mediated ER stress and inhibition of STAT3 in prostate cancer cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 309.	3.5	54
373	Advanced prostate cancer update 2018. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 9-12.	0.7	6
374	Chemohormonal therapy for metastatic hormone-sensitive prostate cancer: An Asian perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, 5-8.	0.7	3
375	Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment. <i>Targeted Oncology</i> , 2018, 13, 679-689.	1.7	15

#	ARTICLE	IF	CITATIONS
376	Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2018, 8, 397.	1.3	20
377	Combining anticancer drugs with osteoprotective agents in prostate cancerâ€”A contemporary update. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 488-497.	0.8	0
378	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. <i>Cancer Treatment Reviews</i> , 2018, 70, 223-231.	3.4	17
379	PSA response following the â€”steroid switchâ€”™ in patients with castrationâ€”resistant prostate cancer treated with abiraterone: A case report. <i>Oncology Letters</i> , 2018, 16, 5383-5388.	0.8	0
380	Immune infiltrates and PD-L1 expression in treatment-naïve acinar prostatic adenocarcinoma: an exploratory analysis. <i>Journal of Clinical Pathology</i> , 2018, 71, 1023-1027.	1.0	11
384	Advancing therapies in metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1797-1804.	0.9	23
385	Case Report #6â€”Bone Metastasis and Its Treatment. , 2018, , 51-61.		0
386	What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 505-517.	0.8	11
387	Androgen Deprivation Therapy for Prostate Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1096, 1-30.	0.8	13
388	Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study. <i>Japanese Journal of Clinical Oncology</i> , 2018, 48, 1012-1021.	0.6	23
390	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2018, 2018, CD012816.	1.5	21
391	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	6.3	901
393	Genitourinary Pathology Reporting Parameters Most Relevant to the Medical Oncologist. <i>Surgical Pathology Clinics</i> , 2018, 11, 877-891.	0.7	0
394	Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. <i>European Journal of Cancer</i> , 2018, 103, 78-87.	1.3	71
395	Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study. <i>Investigational New Drugs</i> , 2018, 36, 1085-1092.	1.2	6
396	Prognostic and predictive models in hormoneâ€”sensitive prostate cancer. <i>BJU International</i> , 2018, 122, 352-353.	1.3	1
397	Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity. <i>Anticancer Research</i> , 2018, 38, 5423-5427.	0.5	11
398	Genome-Based Classification and Therapy of Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 62.	1.3	16

#	ARTICLE	IF	CITATIONS
399	New Insights in Prostate Cancer Development and Tumor Therapy: Modulation of Nuclear Receptors and the Specific Role of Liver X Receptors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2545.	1.8	10
400	Collateral resistance to taxanes in enzalutamide-resistant prostate cancer through aberrant androgen receptor and its variants. <i>Cancer Science</i> , 2018, 109, 3224-3234.	1.7	21
401	Combined androgen blockade achieved better oncological outcome in androgen deprivation therapy for prostate cancer: Analysis of community-based multi-institutional database across Japan using propensity score matching. <i>Cancer Medicine</i> , 2018, 7, 4893-4902.	1.3	18
402	Liquid Biopsy in Prostate Cancer: Circulating Tumor Cells and Beyond. <i>Cancer Treatment and Research</i> , 2018, 175, 87-104.	0.2	12
403	Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer. <i>Targeted Oncology</i> , 2018, 13, 649-655.	1.7	18
405	Novel nomograms for castration-resistant prostate cancer and survival outcome in patients with <i>de novo</i> bone metastatic prostate cancer. <i>BJU International</i> , 2018, 122, 994-1002.	1.3	16
408	MicroRNAs as potential therapeutics to enhance chemosensitivity in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 7820.	1.6	33
410	Systemic treatments for high-risk localized prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 498-510.	1.9	36
411	Lu-177-PSMA treatment for metastatic prostate cancer: case examples of major responses. <i>Clinical and Translational Imaging</i> , 2018, 6, 223-237.	1.1	5
412	Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture?. <i>Cancer</i> , 2018, 124, 3618-3619.	2.0	0
413	Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>Canadian Urological Association Journal</i> , 2018, 12, E365-E372.	0.3	7
414	The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. <i>Urologia Internationalis</i> , 2018, 101, 65-73.	0.6	12
415	Metastatic Prostate Cancer Manifesting as Cholestatic Jaundice: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2018, 2018, 1-4.	0.2	3
416	Local Therapy in Combination with Androgen Deprivation Therapy for Metastatic Prostate Cancer. , 2018, , 189-199.		0
418	Highly branched amine-functionalized <i>p</i> -sulfonatocalix[4]arene decorated with human plasma proteins as a smart, targeted, and stealthy nano-vehicle for the combination chemotherapy of MCF7 cells. <i>New Journal of Chemistry</i> , 2018, 42, 13010-13024.	1.4	25
419	Landmarks in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 627-642.	1.9	78
420	Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. <i>European Urology</i> , 2018, 74, 680-681.	0.9	0
421	Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer. <i>Brachytherapy</i> , 2018, 17, 852-857.	0.2	13

#	ARTICLE	IF	CITATIONS
422	Drug Repositioning for Effective Prostate Cancer Treatment. <i>Frontiers in Physiology</i> , 2018, 9, 500.	1.3	85
423	Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches. <i>Radiation Oncology</i> , 2018, 13, 98.	1.2	19
425	Precision medicine applications in prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591877692.	1.4	12
426	Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1344.	3.4	169
427	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2045-2054.	3.3	116
428	Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 461-472.	2.0	13
429	A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS. <i>PLoS ONE</i> , 2018, 13, e0197606.	1.1	19
430	Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. <i>Prostate</i> , 2018, 78, 1077-1083.	1.2	0
431	Systemic Chemotherapy for Metastatic Hormone-Sensitive Prostate Cancer. , 2018, , 159-165.		0
432	Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review. <i>Yonsei Medical Journal</i> , 2018, 59, 567.	0.9	17
433	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. <i>Radiotherapy and Oncology</i> , 2018, 129, 377-386.	0.3	39
434	Intermittent Chemotherapy with Docetaxel for Metastatic Castration-Resistant Prostate Cancer. , 2018, , 357-368.		0
436	Response to "Why all randomized controlled trials produce biased results". <i>Annals of Medicine</i> , 2018, 50, 545-548.	1.5	1
437	Treatment of hormone-naïve metastatic prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2018, 12, 334-338.	0.5	3
438	Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation. <i>Current Urology Reports</i> , 2018, 19, 79.	1.0	6
439	De novo metastatic castration sensitive prostate cancer: State of art and future perspectives. <i>Cancer Treatment Reviews</i> , 2018, 70, 67-74.	3.4	41
440	Radium 223: Experience of the First 100 Patients in a Regional Centre. <i>Clinical Oncology</i> , 2018, 30, 196.	0.6	0
441	De Novo, Progressed, and Neglected Metastatic Castration-Sensitive Prostate Cancer: Is One Therapy Fit for All?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 482-484.	0.9	4

#	ARTICLE	IF	CITATIONS
442	The role of ketoconazole in current prostate cancer care. <i>Nature Reviews Urology</i> , 2018, 15, 643-651.	1.9	48
443	Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 332-340.	0.9	64
444	Abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a systematic review of “real-life” studies. <i>Therapeutic Advances in Urology</i> , 2018, 10, 305-315.	0.9	16
445	Cancer Treatment-Induced Bone Loss in Women With Breast Cancer and Men With Prostate Cancer. <i>Journal of the Endocrine Society</i> , 2018, 2, 574-588.	0.1	21
446	Options After Chemotherapy for Patients with Metastatic, Castration-Resistant Prostate Cancer. , 2018, , 121-134.		0
447	Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 516-523.	2.0	25
448	Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0191455.	1.1	18
449	Exploring the Role of Enzalutamide in Combination with Radiation Therapy: An <i>In Vitro</i> Study. <i>Anticancer Research</i> , 2018, 38, 3487-3492.	0.5	8
450	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018, 78, 1035-1041.	1.2	11
451	Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 318-324.	0.9	4
452	Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. <i>European Urology Oncology</i> , 2018, 1, 46-53.	2.6	53
453	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. <i>European Urology</i> , 2018, 74, 376-386.	0.9	58
454	Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men. <i>Prostate</i> , 2019, 79, 3-8.	1.2	12
455	Bone-Modifying Agents and Anticancer Agents with Bone Effects. , 2019, , 13-25.		1
456	Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy. <i>European Urology Focus</i> , 2019, 5, 416-424.	1.6	20
457	Importance of non-regional lymph nodes in assigning risk in primary metastatic prostate cancer. <i>BJU International</i> , 2019, 123, 65-73.	1.3	13
458	Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort. <i>Current Problems in Cancer</i> , 2019, 43, 205-212.	1.0	9
459	Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. <i>World Journal of Urology</i> , 2019, 37, 2565-2571.	1.2	10

#	ARTICLE	IF	CITATIONS
460	Sequencing strategies in the new treatment landscape of prostate cancer. <i>Future Oncology</i> , 2019, 15, 2967-2982.	1.1	6
461	The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations. <i>Medical Sciences (Basel, Switzerland)</i> , 2019, 7, 85.	1.3	6
462	Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 688-695.	0.8	29
463	When to keep it simple – adaptive designs are not always useful. <i>BMC Medicine</i> , 2019, 17, 152.	2.3	44
464	The docetaxel debate: impact of chemotherapy in high-risk non-metastatic prostate cancer. <i>Translational Andrology and Urology</i> , 2019, 8, S303-S306.	0.6	5
466	Results of Phase I study on cytoreductive radical prostatectomy in men with newly diagnosed metastatic prostate cancer. <i>Prostate International</i> , 2019, 7, 102-107.	1.2	15
468	Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. <i>Medicines (Basel, Switzerland)</i> , 2019, 6, 82.	0.7	68
469	Quality-of-Life Assessment and Reporting in Prostate Cancer: Systematic Review of Phase 3 Trials Testing Anticancer Drugs Published Between 2012 and 2018. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 332-347.e2.	0.9	9
470	No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer. <i>Prostate</i> , 2019, 79, 1604-1610.	1.2	1
471	Comparative assessment of docetaxel for safety and efficacy between hormone-sensitive and castration-resistant metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 999-1005.	0.8	7
472	Second brazilian consensus on the treatment of advanced prostate cancer: a SBOC-SBU-SBRT panel review. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 449-458.	0.7	6
473	Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy. <i>Quality of Life Research</i> , 2019, 28, 2741-2751.	1.5	21
474	Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 487-499.	1.1	59
475	Time trend and characteristics of prostate cancer diagnosed in Hong Kong (China) in the past two decades. <i>Asian Journal of Andrology</i> , 2019, 21, 104.	0.8	2
477	Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm. <i>Current Treatment Options in Oncology</i> , 2019, 20, 69.	1.3	21
478	Periprostatic Fat Thickness on MRI is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Chinese Patients With Newly Diagnosed Prostate Cancer Treated With Androgen Deprivation Therapy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1036-e1047.	0.9	8
479	Continuing to improve outcomes of men with metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 597-598.	12.5	2
480	Can prostate cancer be NICE?. <i>Clinical Radiology</i> , 2019, 74, 823-830.	0.5	3

#	ARTICLE	IF	CITATIONS
481	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2974-2986.	0.8	643
482	Novel treatment options in the management of metastatic castration-naïve prostate cancer; which treatment modality to choose?. <i>Annals of Oncology</i> , 2019, 30, 1591-1600.	0.6	16
483	Prediction of Postprostatectomy Biochemical Recurrence Using Quantitative Ultrasound Shear Wave Elastography Imaging. <i>Frontiers in Oncology</i> , 2019, 9, 572.	1.3	11
484	Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2019, 17, eGS4414.	0.3	15
485	2019 CUA Annual Meeting Abstracts. <i>Canadian Urological Association Journal</i> , 2019, 13, .	0.3	0
486	Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1493-1495.	13.9	4
487	The future of clinical trials in urological oncology. <i>Nature Reviews Urology</i> , 2019, 16, 722-733.	1.9	5
488	Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 991-998.	0.8	19
489	Plasma Androgen Receptor in Prostate Cancer. <i>Cancers</i> , 2019, 11, 1719.	1.7	13
490	<p>Darolutamide For Castration-Resistant Prostate Cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 8769-8777.	1.0	24
491	Interpreting Oncology Care Model Data to Drive Value-Based Care: A Prostate Cancer Analysis. <i>Journal of Oncology Practice</i> , 2019, 15, e238-e246.	2.5	8
492	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	1.9	71
493	Combining Prostate Cancer Radiotherapy with Therapies Targeting the Androgen Receptor Axis. <i>Current Oncology</i> , 2019, 26, 640-650.	0.9	6
495	Exposure to Docetaxel in the Elderly Patient Population: a Population Pharmacokinetic Study. <i>Pharmaceutical Research</i> , 2019, 36, 181.	1.7	4
497	A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 649-655.	2.6	45
499	The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases. <i>Cancer Control</i> , 2019, 26, 107327481987054.	0.7	16
500	Patientsâ€™ and partnersâ€™ views of care and treatment provided for metastatic castrateâ€™resistant prostate cancer in the UK. <i>European Journal of Cancer Care</i> , 2019, 28, e13140.	0.7	7
501	Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancerâ€™Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. <i>European Urology</i> , 2019, 76, 823-830.	0.9	21

#	ARTICLE	IF	CITATIONS
502	Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm. <i>Journal of Clinical Oncology</i> , 2019, 37, 2957-2960.	0.8	1
503	Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 865-877.	0.6	8
504	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 2961-2967.	0.8	13
505	Docetaxel Combined with Thymoquinone Induces Apoptosis in Prostate Cancer Cells via Inhibition of the PI3K/AKT Signaling Pathway. <i>Cancers</i> , 2019, 11, 1390.	1.7	44
506	Towards Comprehensive Clinical Trial Reporting: The Value of Unpublished Data to Inform Therapeutic Decision-Making in Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1181-e1184.	0.9	0
507	Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better. <i>Journal of Oncological Science</i> , 2019, 5, 45-48.	0.1	0
509	Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer.. <i>Cancers</i> , 2019, 11, 1355.	1.7	54
510	Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 2506-2518.	13.9	403
511	Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. <i>Annals of Oncology</i> , 2019, 30, 1992-2003.	0.6	262
512	The Potential for Chemotherapy-Free Strategies in Advanced Prostate Cancer. <i>Current Urology</i> , 2019, 13, 57-63.	0.4	4
513	Towards precision oncology in advanced prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 645-654.	1.9	156
514	Real-world data: towards achieving the achievable in cancer care. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 312-325.	12.5	187
515	Treatment of Advanced Prostate Cancer. <i>Annual Review of Medicine</i> , 2019, 70, 479-499.	5.0	417
516	Adjuvant Androgen-Deprivation Therapy for Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 633.	3.4	2
517	Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy. <i>JAMA Oncology</i> , 2019, 5, 623.	3.4	25
518	What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations. <i>European Urology Focus</i> , 2019, 5, 162-164.	1.6	7
519	ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 289.e1-289.e9.	0.8	5
520	The Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score is a Novel Significant Prognostic Factor for Patients with Metastatic Prostate Cancer Undergoing Cytoreductive Radical Prostatectomy. <i>Journal of Cancer</i> , 2019, 10, 81-91.	1.2	58

#	ARTICLE	IF	CITATIONS
521	The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity. <i>Medical Oncology</i> , 2019, 36, 18.	1.2	6
522	Oligometastatic prostate cancer: The game is afoot. <i>Cancer Treatment Reviews</i> , 2019, 73, 84-90.	3.4	41
523	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882080.	0.9	2
524	Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models. <i>Cancer Letters</i> , 2019, 446, 62-72.	3.2	10
525	A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 582-598.	0.8	13
526	Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care. <i>European Urology</i> , 2019, 76, 543-545.	0.9	1
527	Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies. <i>Drugs and Aging</i> , 2019, 36, 701-717.	1.3	14
528	New concepts in prostate cancer management: the conundrum of managing oligometastatic disease in prostate cancer through the looking glass darkly. <i>Clinical Radiology</i> , 2019, 74, 865-875.	0.5	10
529	Serum Prognostic Factors of Androgen-deprivation Therapy Among Japanese Men With De Novo Metastatic Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 3191-3195.	0.5	6
530	Oncological Outcome of Cytoreductive Radical Prostatectomy in Prostate Cancer Patients With Bone Oligometastases. <i>Urology</i> , 2019, 131, 166-175.	0.5	19
531	Who Dies From Prostate Cancer? An Analysis of the Surveillance, Epidemiology and End Results Database. <i>Clinical Oncology</i> , 2019, 31, 630-636.	0.6	19
533	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 13-24.	13.9	904
534	The LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levels. <i>BMC Cancer</i> , 2019, 19, 487.	1.1	8
535	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 121-131.	13.9	982
536	This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. <i>Trials</i> , 2019, 20, 264.	0.7	42
537	Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model. <i>Oncology Research and Treatment</i> , 2019, 42, 366-374.	0.8	10
538	Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons. <i>Trials</i> , 2019, 20, 294.	0.7	37
540	Updated recommendations of the International Society of Geriatric Oncology on prostate cancer management in older patients. <i>European Journal of Cancer</i> , 2019, 116, 116-136.	1.3	134

#	ARTICLE	IF	CITATIONS
541	Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 309-320.	1.8	42
542	Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study. Investigative and Clinical Urology, 2019, 60, 195.	1.0	5
543	Castacin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF- κ B signaling pathways. Journal of Food Biochemistry, 2019, 43, e12902.	1.2	90
544	A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer. BMC Urology, 2019, 19, 30.	0.6	5
545	Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer. Cancer Chemotherapy and Pharmacology, 2019, 84, 139-146.	1.1	10
546	Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis. Clinical Genitourinary Cancer, 2019, 17, e806-e813.	0.9	5
547	Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions. Critical Reviews in Oncology/Hematology, 2019, 139, 83-86.	2.0	7
548	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. BJU International, 2019, 124, 373-382.	1.3	11
549	Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody. Cancer Treatment Reviews, 2019, 76, 57-67.	3.4	85
551	Neoadjuvant chemotherapy for high-risk prostatic adenocarcinoma. IJU Case Reports, 2019, 2, 61-64.	0.1	1
552	Interplay Between SOX9, Wnt/ β -Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer. International Journal of Molecular Sciences, 2019, 20, 2066.	1.8	43
553	Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer. Canadian Urological Association Journal, 2019, 13, 396-403.	0.3	10
554	Management algorithms for metastatic prostate cancer. Canadian Urological Association Journal, 2019, 13, 50-60.	0.3	6
557	A novel DNA-binding motif in prostate tumor overexpressed-1 (PTOV1) required for the expression of ALDH1A1 and CCNG2 in cancer cells. Cancer Letters, 2019, 452, 158-167.	3.2	2
558	Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β -catenin in cancer stem-like cells. EBioMedicine, 2019, 42, 397-407.	2.7	63
559	Bone Metastases; Clinical Aspects. , 2019, , 310-319.		3
560	Revisiting Intermittent Therapy in Metastatic Prostate Cancer: Can Less Be More in the "New World Order". European Urology Focus, 2019, 5, 125-133.	1.6	4
561	Androgen Deprivation Therapy with Postprostatectomy Radiotherapy: For Whom and for How Long?. European Urology, 2019, 76, 450-451.	0.9	0

#	ARTICLE	IF	CITATIONS
562	Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2019, 15, 1115-1123.	1.1	9
563	Single-fraction Stereotactic Body Radiation Therapy versus Conventionally Fractionated Radiation Therapy for the Treatment of Prostate Cancer Bone Metastases. <i>Advances in Radiation Oncology</i> , 2019, 4, 314-322.	0.6	9
564	Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. <i>European Journal of Cancer</i> , 2019, 112, 109-117.	1.3	53
565	Radionuclide Therapy of Metastatic Prostate Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 313-325.	2.5	54
566	Cancer- and Chemotherapy-Induced Musculoskeletal Degradation. <i>JBMR Plus</i> , 2019, 3, e10187.	1.3	18
567	Group Lasso Regularized Deep Learning for Cancer Prognosis from Multi-Omics and Clinical Features. <i>Genes</i> , 2019, 10, 240.	1.0	59
568	Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer. <i>Current Oncology Reports</i> , 2019, 21, 43.	1.8	9
569	Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2019, 39, 1391-1396.	0.5	38
570	Systemic treatment for metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2019, 6, 162-168.	0.5	31
571	STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 33-35.	0.4	8
572	Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2019, 36, 199-209.	1.7	8
573	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 686-700.	5.1	496
574	Importance of early treatment in metastatic prostate cancer: a question of life or death. <i>Lancet Oncology</i> , The, 2019, 20, 609-611.	5.1	1
575	The role of hormone therapy and chemotherapy in oligometastatic prostate cancer. <i>ESMO Open</i> , 2019, 4, e000471.	2.0	11
576	Higher Serum Testosterone Levels Associated with Favorable Prognosis in Enzalutamide- and Abiraterone-Treated Castration-Resistant Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 489.	1.0	20
577	Pantoprazole Affecting Docetaxel Resistance Pathways via Autophagy (PANDORA): Phase II Trial of High Dose Pantoprazole (Autophagy Inhibitor) with Docetaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC). <i>Oncologist</i> , 2019, 24, 1188-1194.	1.9	32
578	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. <i>Endocrine-Related Cancer</i> , 2019, 26, R31-R52.	1.6	49
579	Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or enzalutamide. <i>Cancer</i> , 2019, 125, 1777-1788.	2.0	50

#	ARTICLE	IF	CITATIONS
580	Consensus statements on ablative radiotherapy for oligometastatic prostate cancer: A position paper of Italian Association of Radiotherapy and Clinical Oncology (AIRO). <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 24-28.	2.0	32
581	Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 1159-1168.	0.8	112
582	Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently. <i>European Urology Focus</i> , 2019, 5, 119-122.	1.6	8
583	Neutropenia and docetaxel exposure in metastatic castration-resistant prostate cancer patients: A meta-analysis and evaluation of a clinical cohort. <i>Cancer Medicine</i> , 2019, 8, 1406-1415.	1.3	13
585	Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events. <i>Quality of Life Research</i> , 2019, 28, 1191-1199.	1.5	21
586	Biological Evolution of Castration-resistant Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 147-154.	1.6	71
587	Bisphosphonates. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 1018-1030.	0.6	6
588	Zoledronic acid for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 657-666.	0.9	23
589	Effects of prednisone on docetaxel pharmacokinetics in men with metastatic prostate cancer: A randomized drug-drug interaction study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 986-992.	1.1	9
590	Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naïve prostate cancer: a systematic review and meta-analysis. <i>Future Oncology</i> , 2019, 15, 1167-1179.	1.1	8
591	Impact of access to novel therapies on the initial management of castration-resistant prostate cancer: an Australian multicentre study. <i>Internal Medicine Journal</i> , 2019, 49, 1378-1385.	0.5	4
592	Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 352.e19-352.e24.	0.8	0
593	Long-Term Hemodynamic Effects After Carotid Artery Revascularization. <i>Vascular and Endovascular Surgery</i> , 2019, 53, 297-302.	0.3	6
594	Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer. <i>European Urology Focus</i> , 2019, 5, 168-170.	1.6	1
595	Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review. <i>BJU International</i> , 2019, 124, 370-372.	1.3	9
596	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, 17-23.	0.3	17
597	Periungual lesions secondary to chemotherapy with docetaxel. <i>Przegląd Dermatologiczny</i> , 2019, 106, 646-655.	0.0	0
598	A TITAN step forward: apalutamide for metastatic castration-sensitive prostate cancer. <i>Annals of Translational Medicine</i> , 2019, 7, S364-S364.	0.7	6

#	ARTICLE	IF	CITATIONS
600	Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. <i>Cancer Epidemiology</i> , 2019, 63, 101628.	0.8	15
601	Radium-223 in Metastatic Castration-Resistant Prostate Cancer: Clinical Development and Use in Contemporary Practice. <i>Journal of Medical Imaging and Radiation Sciences</i> , 2019, 50, S26-S30.	0.2	2
602	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2019, , .	1.5	1
603	Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer. <i>Prostate International</i> , 2019, 7, 166-170.	1.2	6
604	Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review. <i>European Urology Oncology</i> , 2019, 2, 174-188.	2.6	58
605	Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. <i>European Urology Oncology</i> , 2019, 2, 320-328.	2.6	39
607	TGF- β 2 and microRNA Interplay in Genitourinary Cancers. <i>Cells</i> , 2019, 8, 1619.	1.8	19
608	Combined Modality Therapies for High-Risk Prostate Cancer: Narrative Review of Current Understanding and New Directions. <i>Frontiers in Oncology</i> , 2019, 9, 1273.	1.3	3
609	Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 375-381.	0.6	0
610	Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. <i>Journal of Oncology</i> , 2019, 2019, 1-9.	0.6	24
611	Cancer Stem Cells: Powerful Targets to Improve Current Anticancer Therapeutics. <i>Stem Cells International</i> , 2019, 2019, 1-15.	1.2	44
612	A novel adjuvant drug-device combination tissue scaffold for radical prostatectomy. <i>Drug Delivery</i> , 2019, 26, 1115-1124.	2.5	4
613	A Phase II Study Evaluating Bone Marrow-Sparing, Image-guided Pelvic Intensity-Modulated Radiotherapy (IMRT) With Cesium-131 Brachytherapy Boost, Adjuvant Chemotherapy, and Long-Term Hormonal Ablation in Patients With High Risk, Nonmetastatic Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 285-291.	0.6	7
614	Targeting the androgen receptor and overcoming resistance in prostate cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 175-182.	1.1	36
615	Prostate radiotherapy in newly diagnosed metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 620-628.	0.9	4
616	Monitoring Patients with Metastatic Hormone-Sensitive and Metastatic Castration-Resistant Prostate Cancer: A Multidisciplinary Consensus Document. <i>Cancers</i> , 2019, 11, 1908.	1.7	1
617	Current Insights in the Management of High-risk Prostate Cancer: Still More Questions than Answers. <i>European Urology</i> , 2019, 75, 61-62.	0.9	0
618	Survival of the artificial urinary sphincter in a changing patient profile. <i>World Journal of Urology</i> , 2019, 37, 899-906.	1.2	2

#	ARTICLE	IF	CITATIONS
619	New developments in mechanisms of prostate cancer progression. <i>Seminars in Cancer Biology</i> , 2019, 57, 111-116.	4.3	39
620	Re: Liselotte M.S. BoevÅ©, Maarten C.C.M. Hulshof, AndrÅ© N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. <i>Eur Urol</i> 2019;75:410â€“8. <i>European Urology</i> , 2019, 75, e100.	0.9	3
621	Treatment of Metastatic Prostate Cancer in 2018. <i>JAMA Oncology</i> , 2019, 5, 263.	3.4	16
622	Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 344-352.	0.4	5
623	Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. <i>European Urology</i> , 2019, 75, 817-825.	0.9	17
624	Metastatic bone disease: Pathogenesis and therapeutic options. <i>Journal of Bone Oncology</i> , 2019, 15, 100205.	1.0	153
625	Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial. <i>European Urology</i> , 2019, 76, 306-312.	0.9	26
626	A Territory-wide, Multicenter, Age- and Prostate-specific Antigen-matched Study Comparing Chemohormonal Therapy and Hormonal Therapy Alone in Chinese Men With Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e203-e208.	0.9	6
627	Cabazitaxel inhibits prostate cancer cell growth by inhibition of androgen receptor and heat shock protein expression. <i>World Journal of Urology</i> , 2019, 37, 2137-2145.	1.2	11
628	The clinical significance of perineural invasion in patients with de novo metastatic prostate cancer. <i>Andrology</i> , 2019, 7, 184-192.	1.9	14
629	Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons. <i>European Urology Focus</i> , 2019, 5, 165-167.	1.6	2
630	Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castrationâ€“resistant prostate cancer. <i>Prostate</i> , 2019, 79, 567-573.	1.2	11
631	Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?. <i>European Urology Focus</i> , 2019, 5, 114-116.	1.6	4
632	Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer. <i>Cells</i> , 2019, 8, 43.	1.8	38
633	Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries. <i>Advances in Therapy</i> , 2019, 36, 318-332.	1.3	19
634	Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. <i>European Urology</i> , 2019, 75, 667-675.	0.9	131
635	Interim analysis of the REASSURE (Radium-223 alpha Emitter Agent in non-intervention Safety Study in) Tj ETQq0 0 0 rgBT /Overlock 10 prior use of chemotherapy in routine clinical practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1102-1110.	3.3	35
636	Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency. <i>European Urology</i> , 2019, 75, 184-192.	0.9	69

#	ARTICLE	IF	CITATIONS
637	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 1-14.		0
638	Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian Journal of Urology, 2019, 6, 57-64.	0.5	15
639	Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis. Prostate, 2019, 79, 281-287.	1.2	15
640	Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 710-723.	3.2	12
641	Bone Metastases; Medical Treatment. , 2019, , 320-328.		0
642	Reply to Henry Andr�s Garc�a-Pardo's Letter to the Editor: Liselotte M.S. Borev�, Maarten C.C.M. Hulshof, Andr� N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-418. High-volume Disease Has a Different Standard of Care. European Urology, 2019, 75, e101-e102	0.9	3
643	Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer. BJU International, 2019, 124, 258-267.	1.3	16
644	Management of Metastatic Castration-Na�ve Prostate Cancer. , 2019, , 1-12.		0
645	Management of advanced prostate cancer: A systematic review of existing guidelines and recommendations. Cancer Treatment Reviews, 2019, 73, 54-61.	3.4	28
646	Metastatic prostate cancer remains incurable, why?. Asian Journal of Urology, 2019, 6, 26-41.	0.5	103
647	Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. European Urology, 2019, 75, 410-418.	0.9	375
648	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	0.9	48
649	DNA repair defects in prostate cancer: impact for screening, prognostication and treatment. BJU International, 2019, 123, 769-776.	1.3	35
650	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus, 2019, 5, 381-388.	1.6	12
651	Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology. European Urology, 2019, 75, 88-99.	0.9	333
652	Taxane-based Combination Therapies for Metastatic Prostate Cancer. European Urology Focus, 2019, 5, 369-380.	1.6	23
654	Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial. International Journal of Cancer, 2020, 146, 161-168.	2.3	54
656	Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World Journal of Urology, 2020, 38, 565-591.	1.2	12

#	ARTICLE	IF	CITATIONS
657	Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review. <i>World Journal of Urology</i> , 2020, 38, 601-611.	1.2	6
658	Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group. <i>European Urology Oncology</i> , 2020, 3, 455-463.	2.6	17
659	Temporal changes in survival in men with <i>de novo</i> metastatic prostate cancer: nationwide population-based study. <i>Acta OncolÃ³gica</i> , 2020, 59, 106-111.	0.8	12
660	Pre-treatment ratio of periprostatic to subcutaneous fat thickness on MRI is an independent survival predictor in hormone-naÃve men with advanced prostate cancer. <i>International Journal of Clinical Oncology</i> , 2020, 25, 370-376.	1.0	17
661	Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort. <i>World Journal of Urology</i> , 2020, 38, 1757-1764.	1.2	6
662	Clinical Trial Designs in Oncology. , 2020, , 296-307.e2.		3
664	Bone Metastases. , 2020, , 809-830.e3.		23
665	Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kongâ€™s perspective. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 108-115.	2.0	14
666	Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies. <i>European Urology Focus</i> , 2020, 6, 17-25.	1.6	4
667	Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations. <i>World Journal of Urology</i> , 2020, 38, 681-693.	1.2	12
668	Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 151-167.	1.5	37
669	Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer. <i>European Urology</i> , 2020, 77, 299-308.	0.9	38
670	Reply to Pirus Ghadjar, Thomas Wiegelâ€™s Letter to the Editor re: Elise De Bleser, Barbara Alicja Jereczek-Fossa, David Pasquier, et al. Metastasis-directed Therapy in Treating Nodal Oligorecurrent Prostate Cancer: A Multi-institutional Analysis Comparing the Outcome, Toxicity of Stereotactic Body Radiotherapy, Elective Nodal Radiotherapy. <i>Eur Urol</i> 2019;76:732â€“9. <i>European Urology</i> , 2020, 77, e62-e63.	0.9	2
671	Corticosteroid switch after progression on abiraterone acetate plus prednisone. <i>International Journal of Clinical Oncology</i> , 2020, 25, 240-246.	1.0	7
672	Novel agents for metastatic hormoneâ€sensitive prostate cancer â€ a practice guide for urologists. <i>BJU International</i> , 2020, 125, 342-345.	1.3	6
673	Adverse events related to abiraterone and enzalutamide treatment: analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 199-206.	2.0	20
674	Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>European Urology</i> , 2020, 77, 365-372.	0.9	116
675	Management of bone complications in patients with genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 94-104.	0.8	1

#	ARTICLE	IF	CITATIONS
676	Cytoreductive treatment strategies for de novo metastatic prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 168-182.	12.5	36
677	Observer Agreement and Accuracy of ¹⁸ F-Sodium Fluoride PET/CT in the Diagnosis of Bone Metastases in Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 344-349.	2.8	16
678	Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study. <i>European Urology</i> , 2020, 77, 563-572.	0.9	16
679	Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in Colorectal Cancer In Vitro and In Vivo. <i>Pathology and Oncology Research</i> , 2020, 26, 1957-1969.	0.9	10
681	Bone Metastasis: Current State of Play. <i>Translational Oncology</i> , 2020, 13, 308-320.	1.7	30
682	The effect of androgen deprivation therapy on ⁶⁸ Ga-PSMA tracer uptake in non-metastatic prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 632-641.	3.3	27
683	Conceptual review of key themes in treating prostate cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2020, 11, 893-898.	0.5	1
684	Early Detection of Metastatic Prostate Cancer Relapse on ⁶⁸ Ga-PSMA-11 PET/CT in a Patient Still Exhibiting Biochemical Response. <i>Clinical Nuclear Medicine</i> , 2020, 45, 81-82.	0.7	5
685	Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 222-229.e2.	0.9	5
686	Noncanonical Wnt as a prognostic marker in prostate cancer: "you can't always get what you Wnt". <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 245-254.	1.5	4
687	Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. <i>British Journal of Cancer</i> , 2020, 122, 517-527.	2.9	33
688	A polymeric paste-drug formulation for intratumoral treatment of prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 324-332.	2.0	3
689	Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 395-405.	0.8	450
692	The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, 457-467.	0.8	7
693	Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 1715-1719.	2.9	16
694	Apalutamide for the treatment of metastatic castration-sensitive prostate cancer. <i>Future Oncology</i> , 2020, 16, 2905-2916.	1.1	3
695	Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data. <i>Targeted Oncology</i> , 2020, 15, 709-722.	1.7	17
696	Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 519388.	1.3	18

#	ARTICLE	IF	CITATIONS
697	Prostate Cancer Metastases Are Strongly Inhibited by Agonistic Epha2 Ligands in an Orthotopic Mouse Model. <i>Cancers</i> , 2020, 12, 2854.	1.7	17
698	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020, 15, 477-483.	1.7	4
699	Treatment gains from the "sandwich method" of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience. <i>Translational Andrology and Urology</i> , 2020, 9, 1448-1458.	0.6	0
700	Prostate cancer biology & genomics. <i>Translational Andrology and Urology</i> , 2020, 9, 1481-1491.	0.6	4
701	Metastatic Prostate Cancer: An Update on Treatments and a Review of Patient Symptom Management. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 369-378.	0.3	0
702	The prognostic value of pain in castration-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 654-660.	2.0	7
703	Use of bisphosphonates and other bone supportive agents in the management of prostate cancer – A UK perspective. <i>International Journal of Clinical Practice</i> , 2020, 74, e13611.	0.8	0
704	Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors. , 2020, , 403-420.		0
705	Advances in urologic oncology – OncoForum – The best of 2019. <i>Actas Urológicas Españolas (English) Tj ETQo0 0 0 rgBT /Overlo</i>	0.2	0
706	Newly Diagnosed Oligometastatic Prostate Cancer: Current Controversies and Future Developments. <i>European Urology Oncology</i> , 2022, 5, 587-600.	2.6	8
707	Clinical proteomics for prostate cancer: understanding prostate cancer pathology and protein biomarkers for improved disease management. <i>Clinical Proteomics</i> , 2020, 17, 41.	1.1	20
708	Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, CD013020.	1.5	22
709	Avances en uro-oncología – «OncoForum»: lo mejor del 2019. <i>Actas Urológicas Españolas</i> , 2020, 44, 586-596.	0.3	0
710	Phase II Study of Ipilimumab in Men With Metastatic Prostate Cancer With an Incomplete Response to Androgen Deprivation Therapy. <i>Frontiers in Oncology</i> , 2020, 10, 1381.	1.3	10
711	Prostate-specific Membrane Antigen PET: Therapy Response Assessment in Metastatic Prostate Cancer. <i>Radiographics</i> , 2020, 40, 1412-1430.	1.4	17
712	Metastasis-directed Therapy (SBRT) Guided by PET-CT 18F-CHOLINE Versus PET-CT 68Ga-PSMA in Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of Effectiveness. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 230-236.	0.9	53
713	Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 490-496.	0.7	6
714	Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. <i>Prostate</i> , 2020, 80, 1159-1176.	1.2	11

#	ARTICLE	IF	CITATIONS
715	Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 793.e1-793.e11.	0.8	7
716	Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092006.	1.4	1
717	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	1.5	22
718	AZGP1 Protein Expression in Hormone-Naïve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. <i>Diagnostics</i> , 2020, 10, 520.	1.3	1
719	Nursing Implications of Recent Changes in Management Practices for Metastatic Prostate Cancer. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151047.	0.7	3
720	Prognostic significance of p16 expression in high-grade prostate adenocarcinoma. <i>Pathology International</i> , 2020, 70, 743-751.	0.6	1
721	Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. <i>Scientific Reports</i> , 2020, 10, 12575.	1.6	19
722	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. <i>European Urology Oncology</i> , 2020, 3, 717-724.	2.6	15
723	The evolving options in metastatic castration-sensitive prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2020, 14, 270-275.	0.5	0
725	Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review. <i>Frontiers in Oncology</i> , 2020, 10, 567616.	1.3	11
726	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 80-88.	0.3	9
727	Novel therapies are changing treatment paradigms in metastatic prostate cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 144.	6.9	80
728	Discussion of Treatment Options for Metastatic Hormone Sensitive Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 587981.	1.3	5
729	The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer. <i>Cells</i> , 2020, 9, 2342.	1.8	34
730	Current models, challenges and best practices for work conducted between European academic cooperative groups and industry. <i>ESMO Open</i> , 2020, 5, e000628.	2.0	2
731	Co-targeting PIM and PI3K/mTOR using multikinase inhibitor AUM302 and a combination of AZD-1208 and BEZ235 in prostate cancer. <i>Scientific Reports</i> , 2020, 10, 14380.	1.6	8
732	BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	58
733	Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2278-2287.	1.9	10

#	ARTICLE	IF	CITATIONS
734	Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. <i>European Urology Oncology</i> , 2020, 3, 582-593.	2.6	32
735	Practical Update for the Use of Bone-Targeted Agents in Patients with Bone Metastases from Metastatic Breast Cancer or Castration-Resistant Prostate Cancer. <i>Current Oncology</i> , 2020, 27, 220-224.	0.9	7
736	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. <i>Genome Medicine</i> , 2020, 12, 72.	3.6	35
737	Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer. <i>The Cochrane Library</i> , 2020, 12, CD013245.	1.5	3
738	Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes. <i>European Urology Open Science</i> , 2020, 22, 34-44.	0.2	7
740	Intracranial metastasis from prostate adenocarcinoma: a case report and literature review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2020, 10, 583-586.	0.4	2
741	Management of Advanced Prostate Cancer in Clinical Practice: Real-World Answers to Challenging Dilemmas. <i>JCO Oncology Practice</i> , 2020, 16, 783-789.	1.4	6
742	Biweekly Cabazitaxel Is a Safe Treatment Option for Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients After Docetaxel â€” A Final Analysis of the Prosty II Trial. <i>Anticancer Research</i> , 2020, 40, 6915-6921.	0.5	2
744	Implications of local failure on overall prognosis in aggressive prostate cancer. <i>Translational Andrology and Urology</i> , 2020, 9, 1001-1005.	0.6	1
745	Opening a Scan of Worms. <i>European Urology Oncology</i> , 2020, 3, 725-727.	2.6	0
746	Pharmacologic management of metastatic bone disease. <i>Bone</i> , 2022, 158, 115735.	1.4	3
747	Harnessing the potential of multimodal radiotherapy in prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 321-338.	1.9	15
748	Oligometastatic and Oligoprogression Disease and Local Therapies in Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 137-143.	1.0	20
749	Imaging Intensity and Survival Outcomes in High-Risk Resected Melanoma Treated by Systemic Therapy at Recurrence. <i>Annals of Surgical Oncology</i> , 2020, 27, 3683-3691.	0.7	13
750	Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 483-490.	1.1	3
751	Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study. <i>International Journal of Urology</i> , 2020, 27, 610-617.	0.5	16
752	An overview of platform trials with a checklist for clinical readers. <i>Journal of Clinical Epidemiology</i> , 2020, 125, 1-8.	2.4	72
753	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. <i>Future Oncology</i> , 2020, 16, 1455-1461.	1.1	6

#	ARTICLE	IF	CITATIONS
754	<p>Metastatic Hormone-sensitive Prostate Cancer:ÂCurrent Perspective on the Evolving Therapeutic Landscape</p>. OncoTargets and Therapy, 2020, Volume 13, 3571-3581.	1.0	23
755	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2020, 26, 3230-3238.	3.2	112
756	PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer and Prostatic Diseases, 2020, 23, 549-560.	2.0	36
757	The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis. Cancer Cell International, 2020, 20, 149.	1.8	10
758	Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review. Oncology Research and Treatment, 2020, 43, 299-306.	0.8	17
759	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e89-e106.	1.8	17
760	Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. BMC Cancer, 2020, 20, 398.	1.1	13
761	Comparative study of surgical orchidectomy and medical castration in treatment efficacy, adverse effects and cost based on a large prospective metastatic prostate cancer registry. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 682.e1-682.e9.	0.8	8
762	Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?. Clinical Genitourinary Cancer, 2020, 18, 425-428.	0.9	7
763	Clinical Theragnostic Potential of Diverse miRNA Expressions in Prostate Cancer: A Systematic Review and Meta-Analysis. Cancers, 2020, 12, 1199.	1.7	20
764	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 2020, 78, 29-42.	0.9	110
765	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. Clinical Chemistry, 2020, 66, 842-851.	1.5	25
766	Recent Advances in the Management of High-Risk Localized Prostate Cancer: Local Therapy, Systemic Therapy, and Biomarkers to Guide Treatment Decisions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e241-e252.	1.8	16
767	Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data. Current Opinion in Urology, 2020, 30, 576-583.	0.9	4
768	Treatment of the primary in metastatic prostate cancer. Current Opinion in Urology, 2020, 30, 566-575.	0.9	4
769	Advanced Prostate Cancer: Treatment Advances and Future Directions. Trends in Cancer, 2020, 6, 702-715.	3.8	122
770	The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial. Clinical and Experimental Metastasis, 2020, 37, 551-560.	1.7	16
771	Multidisciplinary total eradication therapy (TET) in men with newly diagnosed oligometastatic prostate cancer. Medical Oncology, 2020, 37, 60.	1.2	12

#	ARTICLE	IF	CITATIONS
773	The role of taxane-based chemotherapy in the treatment of prostate cancer. <i>Current Opinion in Urology</i> , 2020, 30, 527-533.	0.9	5
774	Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 917-926.	0.4	11
775	Epigenetic Analysis of Circulating Tumor DNA in Localized and Metastatic Prostate Cancer: Evaluation of Clinical Biomarker Potential. <i>Cells</i> , 2020, 9, 1362.	1.8	20
776	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>Trials</i> , 2020, 21, 528.	0.7	10
777	An evaluation of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1537-1546.	0.9	8
778	Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. <i>Journal of Clinical Oncology</i> , 2020, 38, 3032-3041.	0.8	37
779	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. <i>BMJ</i> , The, 2020, 369, m115.	3.0	57
780	Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study. <i>Radiation Oncology</i> , 2020, 15, 137.	1.2	22
781	Early Chemotherapy in Metastatic Prostate Cancer Improves Survival: a Quick Note to Surgical Colleagues. <i>Indian Journal of Surgery</i> , 2020, 82, 1206-1211.	0.2	1
782	Cellular rewiring in lethal prostate cancer: the architect of drug resistance. <i>Nature Reviews Urology</i> , 2020, 17, 292-307.	1.9	59
783	The cytoreductive prostatectomy in metastatic prostate cancer: what the individual trials are hoping to answer. <i>BJU International</i> , 2020, 125, 792-800.	1.3	31
784	Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 810-820.	0.6	25
785	Prognostic Value of Germline DNA Repair Gene Mutations in De Novo Metastatic and Castration-Sensitive Prostate Cancer. <i>Oncologist</i> , 2020, 25, e1042-e1050.	1.9	17
787	Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways. <i>International Journal of Biological Sciences</i> , 2020, 16, 1121-1134.	2.6	98
788	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. <i>Prostate</i> , 2020, 80, 527-544.	1.2	34
789	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. <i>Oncology and Therapy</i> , 2020, 8, 209-230.	1.0	37
790	Incidence of second primary malignancies in metastatic castration-resistant prostate cancer: results from observational studies in three countries. <i>Future Oncology</i> , 2020, 16, 1889-1901.	1.1	3
791	Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1119-1134.	0.6	485

#	ARTICLE	IF	CITATIONS
792	Prostate-specific Membrane Antigen Positron Emission Tomography Scans Before Curative Treatment: Ready for Prime Time?. <i>European Urology</i> , 2020, 78, e125-e128.	0.9	3
793	Oral dosing of Recombinant Methioninase Is Associated With a 70% Drop in PSA in a Patient With Bone-metastatic Prostate Cancer and 50% Reduction in Circulating Methionine in a High-stage Ovarian Cancer Patient. <i>Anticancer Research</i> , 2020, 40, 2813-2819.	0.5	38
794	The Evolution of Master Protocol Clinical Trial Designs: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2020, 42, 1330-1360.	1.1	74
795	Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer. <i>EBioMedicine</i> , 2020, 54, 102728.	2.7	65
797	Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Management and Research</i> , 2020, Volume 12, 4369-4377.	0.9	1
798	A Novel Salvage Option for Local Failure in Prostate Cancer, Reirradiation Using External Beam or Stereotactic Radiation Therapy: Systematic Review and Meta-Analysis. <i>Advances in Radiation Oncology</i> , 2020, 5, 965-977.	0.6	29
799	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1769-1776.	0.6	13
800	Enzalutamide plus androgen-deprivation therapy in hormone-sensitive prostate cancer: new perspectives from a current Phase III clinical trial. <i>Future Oncology</i> , 2020, 16, 1511-1523.	1.1	1
801	PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 7.	7.1	45
802	Docetaxel for Early Prostate Cancer: What Have We Learned?. <i>European Urology</i> , 2020, 77, 573-575.	0.9	4
803	Phase I Trial of Weekly Cabazitaxel with Concurrent Intensity Modulated Radiation and Androgen Deprivation Therapy for the Treatment of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 939-947.	0.4	1
804	Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets. <i>Cells</i> , 2020, 9, 460.	1.8	60
805	Can we use disease burden to predict docetaxel activity in metastatic hormone-sensitive prostate cancer?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 55-57.	0.4	0
806	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 486-493.	2.0	4
807	The addition of apalutamide to ADT in the treatment of metastatic castration-sensitive prostate cancer: safety and efficacy. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 147-150.	1.1	3
808	Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 64-75.	1.0	26
809	Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 53-57.	1.0	1
810	Factors to Guide Treatment Selection for Hormone-Sensitive Metastatic Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 76-82.	1.0	5

#	ARTICLE	IF	CITATIONS
811	Neoadjuvant Approaches Prior To Radical Prostatectomy. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 2-12.	1.0	5
812	Radiotherapy in the Management of Metastatic Hormone-Sensitive Prostate Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 87-93.	1.0	4
813	<i>HSD3B1</i> Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2020, 6, e196496.	3.4	50
815	Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release. <i>Pharmaceutical Research</i> , 2020, 37, 36.	1.7	10
816	Circulating cell-free DNA: Translating prostate cancer genomics into clinical care. <i>Molecular Aspects of Medicine</i> , 2020, 72, 100837.	2.7	6
817	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 990-999.	3.2	11
818	Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer. <i>Scientific Reports</i> , 2020, 10, 227.	1.6	42
819	Systemic treatment for metastatic castrate resistant prostate cancer: Does sequence matter?. <i>Prostate</i> , 2020, 80, 399-406.	1.2	12
820	Percent tumor volume vs American Joint Committee on Cancer staging system subclassification for predicting biochemical recurrence in patients with pathologic T2 prostate cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 537-543.	1.2	6
821	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	0.9	278
822	Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients. <i>Clinical Drug Investigation</i> , 2020, 40, 211-226.	1.1	13
823	Bone Health and Bone-Targeted Therapies for Prostate Cancer: ASCO Endorsement of a Cancer Care Ontario Guideline. <i>Journal of Clinical Oncology</i> , 2020, 38, 1736-1743.	0.8	44
824	Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study. <i>PLoS ONE</i> , 2020, 15, e0228447.	1.1	23
825	Radiotherapy to the Primary Tumour for Patients with Metastatic Prostate Cancer: Practice-Changing Results from STAMPEDE. <i>Clinical Oncology</i> , 2020, 32, 327-329.	0.6	3
826	Influence of Baseline Cardiovascular Comorbidities on Mortality after Androgen Deprivation Therapy for Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 189.	1.7	11
827	Tumour innervation and neurosignalling in prostate cancer. <i>Nature Reviews Urology</i> , 2020, 17, 119-130.	1.9	50
828	Yesterday's News is Today's Fish and Chip Paper. <i>Clinical Oncology</i> , 2020, 32, 133-135.	0.6	1
829	61-Year-Old Man With Back Pain, Hematuria, and Lower Extremity Edema. <i>Mayo Clinic Proceedings</i> , 2020, 95, 801-806.	1.4	1

#	ARTICLE	IF	CITATIONS
830	Early Prostate-specific Antigen Response in Men Undergoing Oncological Management for High-Risk Non-metastatic Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 478-479.	0.6	0
831	Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation. <i>Nature Communications</i> , 2020, 11, 1750.	5.8	67
832	Sorting Through the Maze of Treatment Options for Metastatic Castration-Sensitive Prostate Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 198-207.	1.8	5
835	Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 863-868.	1.1	4
836	Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 444-451.	0.9	6
837	Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 8515-8523.	3.3	12
838	Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer. <i>BMC Cancer</i> , 2020, 20, 302.	1.1	10
839	Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model. <i>Canadian Urological Association Journal</i> , 2020, 14, E418-E427.	0.3	4
840	Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 143-151.	3.3	25
841	Multimodal therapy in oligometastatic prostate cancer: A glimpse into the future?. <i>Asian Journal of Urology</i> , 2021, 8, 248-250.	0.5	0
842	Treating De Novo Metastatic Castration-Sensitive Prostate Cancer With Visceral Metastases: An Evolving Issue. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 83-86.	0.9	3
843	Age-related urologic problems in the complex urologic patient. <i>World Journal of Urology</i> , 2021, 39, 1037-1044.	1.2	6
844	The role of 68Gallium-prostate-specific membrane antigen positron emission tomography on staging of high-risk localized prostate cancer: for all high-risk patients or would it be better to select them?. <i>Prostate International</i> , 2021, 9, 54-59.	1.2	1
845	Febrile neutropenia (FN) rates in metastatic hormone sensitive prostate cancer: the role of antibiotics as primary prophylaxis. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 166-168.	2.0	0
846	The development of apalutamide for the treatment of prostate cancer. <i>Expert Opinion on Drug Discovery</i> , 2021, 16, 217-226.	2.5	5
847	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II "2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
848	Association between low prostate-specific antigen levels and greater disease progression in high-grade locally-advanced prostate cancer. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 483-491.	0.8	4
850	To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 389-400.	1.1	2

#	ARTICLE	IF	CITATIONS
851	Management of newly diagnosed metastatic hormone-sensitive prostate cancer: A survey of UK Urologists. <i>International Journal of Clinical Practice</i> , 2021, 75, e13874.	0.8	0
852	Interactions between androgen receptor signaling and other molecular pathways in prostate cancer progression: Current and future clinical implications. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103185.	2.0	41
853	The Role of Theranostics in Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 71-82.	1.0	20
854	Radiopharmaceuticals for Bone Metastases. <i>Seminars in Radiation Oncology</i> , 2021, 31, 45-59.	1.0	6
855	Current and emerging therapies for localized high-risk prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 267-282.	1.1	3
856	Treatment Options in Oligometastatic Disease in Prostate Cancer: Thinking Outside the Box. <i>Current Treatment Options in Oncology</i> , 2021, 22, 2.	1.3	1
857	Apalutamide for metastatic, castration-sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double-blind, placebo-controlled phase 3 TITAN study. <i>International Journal of Urology</i> , 2021, 28, 280-287.	0.5	11
858	Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 544-551.	0.6	1
860	Treatment and resistance mechanisms in castration-resistant prostate cancer: new implications for clinical decision making?. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 149-163.	1.1	4
861	Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 210-219.	2.0	11
862	Survival following upfront chemotherapy for treatment-naïve metastatic prostate cancer: a real-world retrospective cohort study. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 261-267.	2.0	6
863	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 341-348.	2.0	8
864	Navigating systemic therapy for metastatic castration-naïve prostate cancer. <i>World Journal of Urology</i> , 2021, 39, 339-348.	1.2	11
865	Effectiveness and Distribution of Testosterone Levels within First Year of Androgen Deprivation Therapy in a Real-World Setting: Results from the Non-Interventional German Cohort LEAN Study. <i>Urologia Internationalis</i> , 2021, 105, 436-445.	0.6	1
866	Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 419-426.	3.0	15
867	Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). <i>Clinical Cancer Research</i> , 2021, 27, 1967-1973.	3.2	18
868	Circulating Tumor Cells in Prostate Cancer. , 2021, , 93-102.		0
869	Nuclear Imaging for Bone Metastases in Prostate Cancer: The Emergence of Modern Techniques Using Novel Radiotracers. <i>Diagnostics</i> , 2021, 11, 117.	1.3	6

#	ARTICLE	IF	CITATIONS
870	Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2033787.	2.8	5
871	Three-month Prostate-specific Antigen Level After Androgen Deprivation Therapy Predicts Survival in Patients With Metastatic Castration-sensitive Prostate Cancer. <i>In Vivo</i> , 2021, 35, 1101-1108.	0.6	5
872	The Management of Prostate Cancer. <i>Practical Guides in Radiation Oncology</i> , 2021, , 3-23.	0.0	0
873	Current management of metastatic castration-sensitive prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100384.	0.7	7
874	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab082.	1.4	17
875	Cardiovascular Effects of Metabolic Surgery on Type 2 Diabetes. <i>Current Cardiology Reviews</i> , 2021, 16, 275-284.	0.6	2
876	Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592098546.	1.4	1
877	The Role of Androgen Receptor Splicing Variant 7 in Predicting the Prognosis of Metastatic Castration-Resistant Prostate Cancer: Systematic Review and Meta-Analysis. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382110352.	0.8	8
878	Current treatment options for newly diagnosed metastatic hormone-sensitive prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3918-3930.	0.6	10
879	Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer—a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3931-3945.	0.6	3
880	Chronic Treatment of an Advanced Prostate-cancer Patient With Oral Methioninase Resulted in Long-term Stabilization of Rapidly Rising PSA Levels. <i>In Vivo</i> , 2021, 35, 2171-2176.	0.6	14
881	Cancer Treatment-Induced Bone Loss in Hormone-Sensitive Cancer: The Paradigm of Cancer Survivor Bone Health Management. <i>Frontiers of Hormone Research</i> , 2021, 54, 91-102.	1.0	1
882	The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2023, 19, 394.	0.3	0
883	Clinical characteristics and overall survival nomogram of second primary malignancies after prostate cancer, a SEER population-based study. <i>Scientific Reports</i> , 2021, 11, 1293.	1.6	12
884	Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance. <i>BMC Cancer</i> , 2021, 21, 35.	1.1	7
885	SEOM clinical guidelines for the treatment of advanced prostate cancer (2020). <i>Clinical and Translational Oncology</i> , 2021, 23, 969-979.	1.2	18
886	Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice. <i>European Urology Open Science</i> , 2021, 24, 25-33.	0.2	4
887	Căncer de prăstata. <i>Medicine</i> , 2021, 13, 1454-1466.	0.0	0

#	ARTICLE	IF	CITATIONS
888	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
889	Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art. <i>Cancers</i> , 2021, 13, 546.	1.7	27
890	Identification of patients with metastatic castration-sensitive or metastatic castration-resistant prostate cancer using administrative health claims and laboratory data. <i>Current Medical Research and Opinion</i> , 2021, 37, 609-622.	0.9	12
891	Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer. <i>Cancers</i> , 2021, 13, 677.	1.7	6
892	Computational Assessment of Combination Therapy of Androgen Receptor-Targeting Compounds. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 1001-1009.	2.5	4
893	Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. <i>Cancer Science</i> , 2021, 112, 1524-1533.	1.7	19
894	Predicting toxicity-related docetaxel discontinuation and overall survival in metastatic castration-resistant prostate cancer: a pooled analysis of open phase 3 clinical trial data. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 743-749.	2.0	4
895	A Cost-Effectiveness Analysis of Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 627083.	1.3	11
896	Long Non-Coding RNA Landscape in Prostate Cancer Molecular Subtypes: A Feature Selection Approach. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2227.	1.8	2
897	An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks. <i>Journal of Clinical Urology</i> , 0, , 205141582199376.	0.1	1
898	M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting. <i>BJUI Compass</i> , 2021, 2, 159-168.	0.7	8
899	Combination of Platycodin D with docetaxel synergistically suppressed cell growth in DU-145 by enhancing apoptosis and alleviating autophagy. <i>European Journal of Integrative Medicine</i> , 2021, 42, 101302.	0.8	3
900	Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. <i>BMJ Open</i> , 2021, 11, e042953.	0.8	15
901	Metastatic hormone-sensitive prostate cancer: How should it be treated?. <i>World Journal of Clinical Oncology</i> , 2021, 12, 43-49.	0.9	2
902	Radium-223 in the Modern Treatment of Metastatic Castration-resistant Prostate Cancer. <i>Health of Man</i> , 2020, , 71-75.	0.1	0
903	The development of a theory and evidence-based intervention to aid implementation of exercise into the prostate cancer care pathway with a focus on healthcare professional behaviour, the STAMINA trial. <i>BMC Health Services Research</i> , 2021, 21, 273.	0.9	8
904	Current Status and Future Perspectives of Androgen Receptor Inhibition Therapy for Prostate Cancer: A Comprehensive Review. <i>Biomolecules</i> , 2021, 11, 492.	1.8	26
905	Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. <i>Internal Medicine Journal</i> , 2022, 52, 1339-1346.	0.5	9

#	ARTICLE	IF	CITATIONS
906	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. <i>Cancers</i> , 2021, 13, 1290.	1.7	17
907	Radiotherapy of oligometastatic prostate cancer: a systematic review. <i>Radiation Oncology</i> , 2021, 16, 50.	1.2	37
908	Volume matters and intensification is needed: emerging trends in the management of advanced prostate cancer. <i>Drugs in Context</i> , 2021, 10, 1-15.	1.0	0
909	Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective. <i>Current Cancer Drug Targets</i> , 2021, 21, 107-116.	0.8	0
910	Effects of Medical Treatment of Prostate Cancer on Bone Health. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 135-158.	3.1	21
911	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	3.2	19
912	Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response. <i>Frontiers in Oncology</i> , 2020, 10, 627379.	1.3	24
913	Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. <i>Clinical and Translational Imaging</i> , 2021, 9, 215-220.	1.1	5
914	Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naïve disease. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1287-1297.	0.6	1
915	Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer. <i>Journal of Pathology</i> , 2021, 254, 121-134.	2.1	12
916	Intermediate clinical endpoints in localised prostate cancer. <i>Lancet Oncology</i> , The, 2021, 22, 294-296.	5.1	2
917	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 412.	3.4	63
918	Prevention of docetaxel-associated febrile neutropenia with primary granulocyte colony-stimulating factor in Chinese metastatic hormone-sensitive and castration-resistant prostate cancer patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 39-47.	0.7	7
919	Consensus for Treatment of Metastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCDC). <i>JCO Global Oncology</i> , 2021, 7, 550-558.	0.8	6
920	Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4712.	1.8	14
921	¹⁷⁷ Lu-PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 430.	1.4	13
922	Pembrolizumab with or without enzalutamide in selected populations of men with previously untreated metastatic castration-resistant prostate cancer harbouring programmed cell death ligand-1 staining: a retrospective study. <i>BMC Cancer</i> , 2021, 21, 399.	1.1	17
923	Prostate-specific antigen nadir and testosterone level at prostate-specific antigen failure following radiation and androgen suppression therapy for unfavorable-risk prostate cancer and the risk of all-cause and prostate cancer-specific mortality. <i>Cancer</i> , 2021, 127, 2623-2630.	2.0	2

#	ARTICLE	IF	CITATIONS
924	Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 659442.	1.3	3
925	Preoperative exercise interventions to optimize continence outcomes following radical prostatectomy. <i>Nature Reviews Urology</i> , 2021, 18, 259-281.	1.9	29
926	Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells. <i>Molecular Biology Reports</i> , 2021, 48, 3567-3578.	1.0	9
927	Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. <i>Asian Journal of Urology</i> , 2022, 9, 69-74.	0.5	6
928	Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 1274-1305.	0.8	67
929	Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 1688-1699.	0.6	1
930	Optimizing the diagnosis and management of ductal prostate cancer. <i>Nature Reviews Urology</i> , 2021, 18, 337-358.	1.9	21
931	Lowering and Stabilizing PSA Levels in Advanced-prostate Cancer Patients With Oral Methioninase. <i>Anticancer Research</i> , 2021, 41, 1921-1926.	0.5	22
932	Nucleoside-Lipid-Based Nanoparticles for Phenazine Delivery: A New Therapeutic Strategy to Disrupt Hsp27-eIF4E Interaction in Castration Resistant Prostate Cancer. <i>Pharmaceutics</i> , 2021, 13, 623.	2.0	4
933	Long-term outcomes of prostate radiotherapy for newly-diagnosed metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1041-1047.	2.0	13
934	UpFrontPSMA: a randomized phase 2 study of sequential ¹⁷⁷ Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol). <i>BJU International</i> , 2021, 128, 331-342.	1.3	33
935	Digital Medicine in Men with Advanced Prostate Cancer – A Feasibility Study of Electronic Patient-reported Outcomes in Patients on Systemic Treatment. <i>Clinical Oncology</i> , 2021, 33, 751-760.	0.6	7
937	Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1181-1188.	2.0	7
938	Recent Advances in the Treatment of Metastatic Prostate Cancer. <i>Advances in Oncology</i> , 2021, 1, 263-272.	0.1	1
939	Treatment Strategies for Metastatic Castration-Sensitive Prostate Cancer: From “All-Comers” to “Personalized” Approach. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 2967-2974.	1.0	11
940	Cancer Treatment-Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2021, 42, 240-246.	0.1	1
941	A framework for prospective, adaptive meta-analysis (FAME) of aggregate data from randomised trials. <i>PLoS Medicine</i> , 2021, 18, e1003629.	3.9	21
942	Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival. <i>Advances in Therapy</i> , 2021, 38, 3831-3841.	1.3	4

#	ARTICLE	IF	CITATIONS
943	Eggmanone Effectively Overcomes Prostate Cancer Cell Chemoresistance. <i>Biomedicines</i> , 2021, 9, 538.	1.4	1
944	Prognostic Value of BRCA1 and BRCA2 Gene Mutations in Prostate Cancer: a Literature Review. <i>Kreativna Ć Hirurĳi Ć I Onkologi Ć</i> , 2021, 11, 183-187.	0.1	1
945	Triple-arm androgen blockade for advanced prostate cancer: a review. <i>Medical Oncology</i> , 2021, 38, 75.	1.2	4
946	2020 Korean guidelines for the management of metastatic prostate cancer. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 491-514.	0.7	5
947	Cross-resistance and drug sequence in prostate cancer. <i>Drug Resistance Updates</i> , 2021, 56, 100761.	6.5	36
949	Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 658331.	1.3	6
950	Combination Treatment Options for Castration-Resistant Prostate Cancer. , 0, , 59-80.		5
951	Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer. <i>Cells</i> , 2021, 10, 1133.	1.8	13
952	Dynamics of conditional survival and risk factors in androgen deprivation therapy for prostate cancer using a multi-Ćinstitutional Japan-Ćwide database. <i>International Journal of Urology</i> , 2021, 28, 927-935.	0.5	2
953	Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high-Ćand middle-Ćincome Asian countries. <i>Cancer Science</i> , 2021, 112, 2071-2080.	1.7	9
954	Computer extracted gland features from H&E predicts prostate cancer recurrence comparably to a genomic companion diagnostic test: a large multi-site study. <i>Npj Precision Oncology</i> , 2021, 5, 35.	2.3	13
955	Androgen Receptor Splice Variant 7 Predicts Shorter Response in Patients with Metastatic Hormone-sensitive Prostate Cancer Receiving Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 79, 879-886.	0.9	26
956	Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2021, 55, 1145-1154.	0.8	31
957	Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options. <i>Oncologist</i> , 2021, 26, 956-964.	1.9	7
958	Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with <i>De Novo</i> Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4549-4556.	3.2	5
959	Individualized Bone-Protective Management in Long-Term Cancer Survivors With Bone Metastases. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1906-1913.	3.1	3
961	Novel insights in cell cycle dysregulation during prostate cancer progression. <i>Endocrine-Related Cancer</i> , 2021, 28, R141-R155.	1.6	16
962	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 199-207.	2.0	3

#	ARTICLE	IF	CITATIONS
963	USE OF ^{177}Lu -PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER. <i>Siberian Journal of Oncology</i> , 2021, 20, 115-123.	0.1	3
964	β -elemenic acid inhibits growth and triggers apoptosis in human castration-resistant prostate cancer cells through the suppression of JAK2/STAT3/MCL-1 and NF- κ B signal pathways. <i>Chemico-Biological Interactions</i> , 2021, 342, 109477.	1.7	16
965	Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies. <i>Current Osteoporosis Reports</i> , 2021, 19, 452-461.	1.5	0
966	Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial). <i>Scientific Reports</i> , 2021, 11, 12470.	1.6	3
967	“The use of bisphosphonates to treat skeletal complications in solid tumours” <i>Bone</i> , 2021, 147, 115907.	1.4	19
968	Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer. <i>BMC Research Notes</i> , 2021, 14, 227.	0.6	3
969	A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1685-1728.	0.9	4
970	High-Throughput Imaging Assay for Drug Screening of 3D Prostate Cancer Organoids. <i>SLAS Discovery</i> , 2021, 26, 1107-1124.	1.4	30
971	Repurposing metformin as anticancer drug: Randomized controlled trial in advanced prostate cancer (MANSMED). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 831.e1-831.e10.	0.8	25
972	“New Kids on the Block” The Game Changers. The Role of Immune Check Point Blockade in Personalised Treatment of Prostate, Urinary Bladder and Kidney Cancer. <i>Proceedings of the Latvian Academy of Sciences</i> , 2021, 75, 149-157.	0.0	1
973	Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. <i>Cancers</i> , 2021, 13, 2844.	1.7	10
974	Prise en charge du cancer de la prostate oligométrique par le traitement local, mais curatif, à l'aide des imageries métaboliques et de la radiothérapie stéréotaxique. <i>Progrès En Urologie - FMC</i> , 2021, 31, F41-F46.	0.2	0
975	Outcomes of metastasis-directed therapy of bone oligometastatic prostate cancer. <i>Radiation Oncology</i> , 2021, 16, 125.	1.2	17
976	Olaparib for the treatment of metastatic prostate cancer. <i>Future Oncology</i> , 2021, 17, 2413-2429.	1.1	2
977	Narrative review of management strategies and outcomes in node-positive prostate cancer. <i>Translational Andrology and Urology</i> , 2021, 10, 3176-3187.	0.6	3
978	Oligometastatic prostate cancer: definition and the role of local and systemic therapy: a narrative review. <i>Translational Andrology and Urology</i> , 2021, 10, 3167-3175.	0.6	9
979	Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2021, 1867, 166129.	1.8	11
980	Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7178.	1.8	6

#	ARTICLE	IF	CITATIONS
981	Adverse events related to radium-223 treatment: "real-life" data from the Eudra-Vigilance database. <i>Minerva Urology and Nephrology</i> , 2021, 73, 342-348.	1.3	8
982	Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. <i>European Journal of Cancer</i> , 2021, 157, 485-492.	1.3	7
983	Bone metastasis: mechanisms, therapies, and biomarkers. <i>Physiological Reviews</i> , 2021, 101, 797-855.	13.1	153
984	Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. <i>Cancer Science</i> , 2021, 112, 3616-3626.	1.7	8
985	Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1665-1671.	0.6	2
986	A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2021, 80, 82-94.	0.9	53
987	Local Therapies in Oligometastatic and Oligoprogressive Prostate Cancer. <i>Seminars in Radiation Oncology</i> , 2021, 31, 242-249.	1.0	7
988	Revision of CHARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients. <i>Prostate International</i> , 2021, 9, 208-214.	1.2	5
989	Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. <i>EJNMMI Research</i> , 2021, 11, 61.	1.1	16
990	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	1.3	4
991	Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. <i>BJU International</i> , 2022, 129, 423-433.	1.3	37
992	Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. <i>Journal of Urology</i> , 2021, 206, 1420-1429.	0.2	24
993	Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine. <i>Medical Oncology</i> , 2021, 38, 116.	1.2	9
994	Prostate-Specific Antigen Kinetics Effects on Outcomes of Low-Volume Metastatic Prostate Cancer Patients Receiving Androgen Deprivation Therapy. <i>Journal of Oncology</i> , 2021, 2021, 1-10.	0.6	4
996	Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4209.	1.7	6
997	Bone Health in Patients With Prostate Cancer: An Evidence-Based Algorithm. , 2021, 38, S20-S26.		2
998	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021, 4, 543-552.	2.6	11
999	Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 274-282.	2.0	11

#	ARTICLE	IF	CITATIONS
1000	A Review on the Current Treatment Paradigm in High-Risk Prostate Cancer. <i>Cancers</i> , 2021, 13, 4257.	1.7	10
1001	Radiation treatment in prostate cancer: covering the waterfront. <i>BJU International</i> , 2021, 128, 398-407.	1.3	3
1002	Use of docetaxel in low- and high-burden metastatic hormone-sensitive prostate cancer: A systematic review and assessment of subgroup analyses. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 1743-1750.	0.5	1
1003	High Tumor Burden Predicts Poor Response to Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Cancers</i> , 2021, 13, 3966.	1.7	4
1004	Salvage local treatment for localized radio-recurrent prostate cancer: a narrative review and future perspectives. <i>Future Oncology</i> , 2021, 17, 4207-4219.	1.1	0
1005	Efficacy of Neoadjuvant Chemohormonal Therapy in Oligometastatic Hormone-Sensitive Prostate Cancer: A Prospective, Three-Arm, Comparative Propensity Score Match Analysis. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e223-e234.	0.9	1
1006	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021, 144, 1295-1307.	1.6	75
1007	Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). <i>BJU International</i> , 2022, 129, 699-707.	1.3	19
1008	Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer. <i>Cancers</i> , 2021, 13, 3947.	1.7	5
1010	Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2938-2947.	0.8	18
1011	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951.	1.7	19
1012	Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 53-58.	2.0	7
1013	Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer. <i>Prostate International</i> , 2021, 9, 113-118.	1.2	24
1014	Chemotherapy in metastatic castration-resistant prostate cancer: Current scenario and future perspectives. <i>Cancer Letters</i> , 2021, 523, 162-169.	3.2	24
1015	RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting. <i>Contemporary Clinical Trials</i> , 2021, 108, 106481.	0.8	2
1016	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. <i>European Urology</i> , 2021, 80, 275-279.	0.9	28
1017	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	0.5	11
1018	Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHARTED trial. <i>Annals of Oncology</i> , 2021, 32, 1157-1166.	0.6	43

#	ARTICLE	IF	CITATIONS
1019	Brain metastasis from prostate cancer: A review of the literature with an illustrative case. <i>International Journal of Surgery Open</i> , 2021, 37, 100419.	0.2	4
1020	Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics. <i>Neoplasia</i> , 2021, 23, 851-858.	2.3	31
1021	Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness. <i>Radiology</i> , 2021, 300, 594-604.	3.6	8
1022	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	1.4	75
1023	Prostate cancer. <i>Lancet, The</i> , 2021, 398, 1075-1090.	6.3	240
1024	Ultrasound-mediated microbubbles cavitation enhanced chemotherapy of advanced prostate cancer by increasing the permeability of blood-prostate barrier. <i>Translational Oncology</i> , 2021, 14, 101177.	1.7	17
1025	Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. <i>European Urology</i> , 2021, 80, 522-523.	0.9	5
1026	Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e326-e333.	0.9	7
1027	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 4061-4068.	0.8	24
1028	Small Steps and Giant Leaps, or Just Getting on with It?. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab083.	1.4	0
1029	The treatment landscape of metastatic prostate cancer. <i>Cancer Letters</i> , 2021, 519, 20-29.	3.2	50
1030	An update from the ReIMAGINE Prostate Cancer Risk Study (NCT04060589): A prospective cohort study in men with a suspicion of prostate cancer who are referred onto a magnetic resonance imaging-based diagnostic pathway with donation of tissue, blood, and urine for biomarker analyses. <i>European Urology</i> , 2021, 80, 398-399.	0.9	1
1031	Evasion of cell death: A contributory factor in prostate cancer development and treatment resistance. <i>Cancer Letters</i> , 2021, 520, 213-221.	3.2	16
1032	Docetaxel Treatment for Metastatic Hormone-sensitive Prostate Cancer in Daily Practice. <i>European Urology Open Science</i> , 2021, 33, 48-55.	0.2	2
1033	Unexpected massive bleeding caused by extensive maxillary osteonecrosis in a breast cancer patient: a case report. <i>Translational Cancer Research</i> , 2021, 10, 5014-5021.	0.4	3
1034	High rates of advanced prostate cancer in the Middle East: Analysis from a tertiary care center. <i>Urology Annals</i> , 2021, 13, 418.	0.3	6
1035	Current Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 107-147.	0.8	3
1036	Age, Gleason Score, and PSA are important prognostic factors for survival in metastatic castration-resistant prostate cancer. Results of The Uroncor Group (Uro-Oncological Tumors) of the Spanish Society of Radiation Oncology (SEOR). <i>Clinical and Translational Oncology</i> , 2020, 22, 1378-1389.	1.2	11

#	ARTICLE	IF	CITATIONS
1037	Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100256.	0.7	10
1038	Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group. <i>Journal of Bone Oncology</i> , 2020, 25, 100311.	1.0	27
1039	Estimating the healthcare costs of treating prostate cancer in Australia: A Markov modelling analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 91.e7-91.e15.	0.8	11
1041	Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients. <i>American Journal of Therapeutics</i> , 2020, Publish Ahead of Print, e380-e387.	0.5	2
1043	Editorial Comment to Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. <i>International Journal of Urology</i> , 2016, 23, 370-370.	0.5	2
1044	Taxane resistance in prostate cancer is mediated by decreased drug-target engagement. <i>Journal of Clinical Investigation</i> , 2020, 130, 3287-3298.	3.9	31
1045	Added value of 68Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous 99mTc bone scintigraphy. <i>EJNMMI Research</i> , 2020, 10, 31.	1.1	31
1046	¹⁸ F-Fluciclovine PET metabolic imaging reveals prostate cancer tumour heterogeneity associated with disease resistance to androgen deprivation therapy. <i>EJNMMI Research</i> , 2020, 10, 143.	1.1	12
1047	Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. <i>JCO Oncology Practice</i> , 2020, 16, e201-e210.	1.4	13
1048	p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. <i>Endocrine-Related Cancer</i> , 2020, 27, 187-198.	1.6	17
1049	Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. <i>Oncotarget</i> , 2016, 7, 64447-64470.	0.8	130
1050	Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1 α and sphingosine kinase 1. <i>Oncotarget</i> , 2016, 7, 80943-80956.	0.8	32
1051	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. <i>Oncotarget</i> , 2017, 8, 44131-44140.	0.8	16
1052	Prostate Tumor Overexpressed-1 (PTOV1) promotes docetaxel-resistance and survival of castration resistant prostate cancer cells. <i>Oncotarget</i> , 2017, 8, 59165-59180.	0.8	15
1053	Time to progression to castration-resistant prostate cancer after commencing combined androgen blockade for advanced hormone-sensitive prostate cancer. <i>Oncotarget</i> , 2018, 9, 36966-36974.	0.8	26
1054	Cartilage oligomeric matrix protein in patients with osteoarthritis is independently associated with metastatic disease in prostate cancer. <i>Oncotarget</i> , 2019, 10, 4776-4785.	0.8	6
1055	Medical management of metastatic prostate cancer. <i>Australian Prescriber</i> , 2018, 41, 154-159.	0.5	11
1056	Using circulating tumor cells to advance precision medicine in prostate cancer. <i>Journal of Cancer Metastasis and Treatment</i> , 2017, 3, 190.	0.5	8

#	ARTICLE	IF	CITATIONS
1057	Overcoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathways. , 2020, 3, 726-741.		6
1058	The STAMPEDE trial: paradigm-changing data through innovative trial design. Translational Cancer Research, 2016, 5, S485-S490.	0.4	15
1059	A Clinical Evaluation of Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer: Guiding Principles for Treatment Selection and Perspectives on Research. OncoTargets and Therapy, 2020, Volume 13, 13247-13263.	1.0	8
1060	Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions. Current Cancer Drug Targets, 2019, 19, 368-381.	0.8	9
1061	Multimodal Primary Treatment of Metastatic Prostate Cancer with Androgen Deprivation and Radiation. Anticancer Research, 2016, 36, 6439-6448.	0.5	10
1062	Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells. Anticancer Research, 2018, 38, 2045-2055.	0.5	5
1063	Enhanced Patient Activation in Cancer Care Transitions: Protocol for a Randomized Controlled Trial of a Tailored Electronic Health Intervention for Men With Prostate Cancer. JMIR Research Protocols, 2019, 8, e11625.	0.5	10
1064	Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 508-515.	3.9	7
1065	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 445-456.	3.9	8
1066	In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer. Life Science Alliance, 2020, 3, e202000770.	1.3	15
1067	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	1.3	22
1068	The Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer Treated With Novel Hormonal Therapy or Chemotherapy: A Systematic Review and Meta-analysis. Frontiers in Oncology, 2020, 10, 572590.	1.3	11
1069	Cardiovascular Complications of Prostate Cancer Treatment. Frontiers in Pharmacology, 2020, 11, 555475.	1.6	14
1070	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers, 2020, 12, 1178.	1.7	10
1071	Presenting Stage and Risk Group in Men Dying of Prostate Cancer. Current Oncology, 2020, 27, 547-551.	0.9	2
1072	Minimally effective concentration of zoledronic acid to suppress osteoclasts. Experimental and Therapeutic Medicine, 2018, 15, 5330-5336.	0.8	7
1073	Chemotherapy options in castration-resistant prostate cancer. Indian Journal of Urology, 2016, 32, 262.	0.2	19
1074	Immunotherapy in metastatic prostate cancer. Indian Journal of Urology, 2016, 32, 271.	0.2	6

#	ARTICLE	IF	CITATIONS
1075	Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. Asian Journal of Andrology, 2017, 19, 143.	0.8	23
1076	The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines. Asian Journal of Andrology, 2019, 21, 460.	0.8	26
1077	Impact of taxanes on androgen receptor signaling. Asian Journal of Andrology, 2019, 21, 249.	0.8	12
1078	Role of chemotherapy in prostate cancer. Asian Journal of Andrology, 2018, 20, 221.	0.8	85
1079	Current concepts and trends in the treatment of bone metastases in patients with advanced prostate cancer. Asian Journal of Andrology, 2019, 21, 12.	0.8	5
1080	Experience with using fosfestrol for treating metastatic castrate-resistant prostate cancer in resource-limited setting. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 79-84.	0.1	1
1081	Neoadjuvant therapy in high-risk prostate cancer. Indian Journal of Urology, 2020, 36, 251.	0.2	6
1082	STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs. Indian Journal of Urology, 2018, 34, 180.	0.2	7
1083	Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017. Urology Annals, 2018, 10, 138.	0.3	12
1084	The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer. Investigative and Clinical Urology, 2020, 61, S3.	1.0	3
1085	Bone Health Issues in Patients with Prostate Cancer: An Evidence-Based Review. World Journal of Men's Health, 2020, 38, 151.	1.7	7
1086	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 479-505.	2.3	943
1087	Contemporary Population-Based Analysis of Bone Mineral Density Testing in Men Initiating Androgen Deprivation Therapy for Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1374-1381.	2.3	7
1088	Bone Health in Cancer Patients. UNIPA Springer Series, 2021, , 365-380.	0.1	0
1089	Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer. Clinical Medicine Insights: Oncology, 2021, 15, 117955492110497.	0.6	3
1090	Prostate Cancer: Advanced and Metastatic Disease. UNIPA Springer Series, 2021, , 805-821.	0.1	0
1091	Osteoporosis Management with Focus on Spine. , 2021, , 61-92.		0
1092	Canadian Urologic Association best practice report: Bone health in prostate cancer. Canadian Urological Association Journal, 2021, 15, 375-382.	0.3	3

#	ARTICLE	IF	CITATIONS
1093	Mortality in men with castration-resistant prostate cancer: A long-term follow-up of a population-based real-world cohort. <i>BJU Compass</i> , 2022, 3, 173-183.	0.7	12
1094	Secondary Hyperparathyroidism, Bone Density, and Bone Turnover After Bariatric Surgery: Differences Between Roux-en-Y Gastric Bypass and Sleeve Gastrectomy. <i>Obesity Surgery</i> , 2021, 31, 5367-5375.	1.1	12
1095	Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer. <i>Prostate</i> , 2021, 82, 182.	1.2	4
1096	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. <i>Prostate</i> , 2022, 82, 120-131.	1.2	2
1097	Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer. <i>BJU International</i> , 2021, 128, 18-26.	1.3	3
1098	Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. , 2021, 9, e002919.		30
1099	Treatment of Advanced Prostate Cancer. , 2005, , 18-25.		5
1100	Abiraterone Acetate in Patients with Advanced Castrate Resistant Prostate Cancer: Initial Real Life Experience in 2 Cancer Units. <i>Journal of Analytical Oncology</i> , 2016, 5, 42-46.	0.1	1
1102	Bone-Targeted Agents. , 2017, , 181-192.		0
1103	Approaches for Assessment of Response of Bone Metastases to Therapies. , 2017, , 223-249.		0
1104	Bone Metastases from Prostate Cancer: Hormonal Therapy. , 2017, , 105-120.		0
1105	Combinations of Hormonal Therapy and Chemotherapy. , 2017, , 135-146.		0
1106	Bone-Seeking Radionuclide for Therapy. , 2017, , 193-207.		0
1108	Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer. <i>Journal of Cancer Therapy</i> , 2017, 08, 1149-1159.	0.1	0
1109	Molecular Pathogenesis of Prostate Cancer. , 2017, , 171-189.		0
1110	Management of Prostate Cancer. , 2017, , 19-26.		0
1111	First-Line Hormonal Manipulation: Surgical and Medical Castration with LHRH Agonists and Antagonists, Steroids, and Pure Antiandrogens. , 2017, , 313-325.		0
1112	Combined chemohormonalradiation treatment of highand very-high-risk non-metastatic prostate cancer. <i>Onkourologiya</i> , 2017, 13, 101-111.	0.1	1

#	ARTICLE	IF	CITATIONS
1113	Korean Treatment Guidelines for Metastatic Prostate Cancer Developed by the Korean Association for Clinical Oncology. Korean Journal of Medicine, 2017, 92, 124-141.	0.1	2
1114	Chemotherapy With Androgen Deprivation for Hormone-Naïve Prostate Cancer. The Korean Journal of Urological Oncology, 2017, 15, 11-15.	0.1	0
1115	A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer. Oncotarget, 2017, 8, 96893-96902.	0.8	4
1117	Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer. , 2017, 37, 5631-5637.		2
1118	The Role of Androgen Receptor in Prostate Cancer. Molecular Pathology Library, 2018, , 345-365.	0.1	1
1119	Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. Onkourologiya, 2018, 13, 85-90.	0.1	1
1120	Evaluation and Treatment for High-Risk Prostate Cancer. , 2018, , 135-156.		0
1121	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2018, , 1-14.		0
1122	Side Effects of Medical Cancer Therapy in Genitourinary Malignancies. , 2018, , 179-212.		0
1123	Superiority and Non-inferiority Phase III Oncology Trials. , 2018, , 203-216.		0
1124	Bone-Targeted Treatment in CRPC Management. , 2018, , 317-325.		0
1125	Radical Prostatectomy in the Metastatic Setting. , 2018, , 169-184.		0
1126	Endokrines System und Immunmodulation. , 2018, , 721-796.		0
1127	Prostatakarzinom. , 2018, , 305-368.		0
1129	Combination of nuclear NF- κ B/p65 localization and gland morphological features from surgical specimens appears to be predictive of early biochemical recurrence in prostate cancer patients. , 2018, , .		0
1130	The role of taxanes in prostate cancer: literature review. Onkourologiya, 2018, 14, 130-141.	0.1	0
1131	Bone-Targeted Therapies in Adjuvant Setting. , 2019, , 27-39.		0
1132	Role of the androgen signaling axis in genitourinary malignancies. Translational Cancer Research, 2018, 7, 1135-1142.	0.4	2

#	ARTICLE	IF	CITATIONS
1133	Retrospective Analysis of Clinico-Epidimological Factors in Prostatic Cancer. The Egyptian Journal of Hospital Medicine, 2018, 73, 6075-6081.	0.0	0
1136	Separate Chinese lines for prostate cancer?. Asian Journal of Andrology, 2019, 21, 212.	0.8	0
1137	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
1139	Metastatic hormone-sensitive prostate cancer: Practical guidelines and optimization of therapy selection. Onkourologiya, 2019, 14, 139-149.	0.1	2
1140	Management of Metastatic Castration-Na~ve Prostate Cancer. , 2019, , 277-288.		0
1141	Systemic Treatment of Castration-Resistant Metastatic Prostate Cancer. , 2019, , 241-253.		0
1142	Impact of functional imaging in prostate cancer: a clinical point of view. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019, 63, 1-6.	0.4	0
1143	Radiomic features derived from pre-operative multi-parametric MRI of prostate cancer are associated with Decipher risk score. , 2019, , .		0
1144	Nanoparticles as theranostic vehicles in prostate cancer. Annals of Translational Medicine, 2019, 7, S29-S29.	0.7	1
1145	Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit?. European Journal of Hospital Pharmacy, 2021, 28, 83-87.	0.5	1
1146	New treatment options in hormone-sensitive prostate cancer. Onkologie (Czech Republic), 2019, 13, 150-156.	0.0	0
1147	Chemotherapy of Prostatic Adenocarcinoma : State of the Art 2019. Integrative Journal of Medical Sciences, 0, 6, .	0.0	0
1148	New possibilities of combined antiandrogen therapy in patients with metastatic hormone-sensitive prostate cancer. Onkourologiya, 2019, 15, 89-101.	0.1	0
1149	Clinical studies of chemotherapy efficacy in combination with androgenic deprivation in patients with oligometastatic hormone-sensitive prostate cancer. Meditsinskiy Sovet, 2019, , 170-175.	0.1	0
1150	The Current Status of Metastatic Castration-Na~ve Prostate Cancer Management. The Korean Journal of Urological Oncology, 2020, 18, 11-17.	0.1	0
1151	Rubimaillin suppresses proliferation, migration and invasion of prostate cancer cells via the Notch-1/MMP signaling pathway. Cellular and Molecular Biology, 2020, 66, 130-134.	0.3	2
1152	Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma. American Journal of Case Reports, 2020, 21, e925181.	0.3	3
1153	C~ncer de pr~stata metast~sico hormono-sensible : ~mo deber~amos tratar a nuestros pacientes?. Revista Colombiana De Hematolog~a Y Oncolog~a, 2020, 7, 7-9.	0.0	0

#	ARTICLE	IF	CITATIONS
1154	Comparative Effectiveness of All Available Treatments for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-analysis. <i>American Journal of Therapeutics</i> , 2020, 27, e541-e543.	0.5	2
1155	Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era. <i>Cancer Medicine</i> , 2021, 10, 7909-7920.	1.3	2
1156	Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration. <i>Cancer Medicine</i> , 2021, 10, 8570-8580.	1.3	22
1157	LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis. <i>Indian Journal of Urology</i> , 2020, 36, 71.	0.2	0
1158	Silica-Based Nanoparticles as Drug Delivery Vehicles for Prostate Cancer Treatment. <i>Chemical Record</i> , 2021, 21, 1535-1568.	2.9	12
1159	Choice of treatment options for metastatic hormone-sensitive prostate cancer. <i>Meditinskiy Sovet</i> , 2020, , 90-99.	0.1	0
1160	Cáncer de próstata metastásico hormono-sensible: ¿Cómo deberíamos tratar a nuestros pacientes?. <i>Revista Colombiana De Hematología Y Oncología</i> , 2020, 7, .	0.0	0
1161	Effectiveness of hormone therapy in patients with prostate cancer. Regional experience. <i>IssledovaniĀ i Praktika V Medicine</i> , 2020, 7, 79-93.	0.1	0
1162	Endothelial Cells Promote Docetaxel Resistance of Prostate Cancer Cells by Inducing ERG Expression and Activating Akt/mTOR Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 584505.	1.3	12
1163	Prostatakarzinom beim geriatrischen Patienten. , 2020, , 141-172.		0
1164	Metastatic and Secondary Orbital Tumors. , 2020, , 1-15.		0
1165	Molecular mechanisms of docetaxel resistance in prostate cancer. , 2020, 3, 676-685.		11
1166	Chemotherapeutic Agents for Urologic Oncology: Basic Principles. , 2020, , 611-637.		0
1167	ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. , 2020, , B-1-B30-3.		0
1168	Optimizing anticancer therapy in newly diagnosed metastatic castration sensitive prostate cancer. <i>Hellenic Urology</i> , 2020, 32, 128.	0.1	0
1169	Immunotherapy in Advanced Prostate Cancer. <i>European Oncology and Haematology</i> , 2020, 16, 44.	0.0	0
1171	Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. <i>BJU International</i> , 2021, , .	1.3	5
1172	High-Grade, Low Prostate-Specific Antigen Prostate Cancer: Unique Hormone-Resistant Entity with Poor Survival. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2020, 41, 481-483.	0.1	0

#	ARTICLE	IF	CITATIONS
1173	Recent Developments in the Management of Advanced Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 969-972.	2.3	1
1174	Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer. Nuklearmedizin - NuclearMedicine, 2020, 59, 365-374.	0.3	2
1177	Radium-223 IN metastatic hormone-sensitive high-grade prostate cancer: initial experience. American Journal of Nuclear Medicine and Molecular Imaging, 2017, 7, 236-245.	1.0	8
1178	The impact of celecoxib on outcomes in advanced prostate cancer patients undergoing androgen deprivation therapy. American Journal of Clinical and Experimental Urology, 2018, 6, 123-132.	0.4	1
1179	Treatment of Advanced Prostate Cancer. Missouri Medicine, 2018, 115, 156-161.	0.3	8
1180	Commentary on local therapy in men who present with a metastatic prostate cancer from special issue senior guest editor. American Journal of Clinical and Experimental Urology, 2019, 7, 61-63.	0.4	0
1181	Real-World Treatment Patterns in Patients with Castrate-Resistant Prostate Cancer and Bone Metastases. American Health and Drug Benefits, 2019, 12, 142-149.	0.5	11
1182	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. BMJ Open, 2019, 9, e034708.	0.8	2
1183	TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer. Indian Journal of Urology, 2020, 36, 144-145.	0.2	0
1184	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. Indian Journal of Urology, 2021, 37, 72-78.	0.2	0
1186	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211051870.	1.4	1
1187	Epigenetics and precision medicine in prostate cancer. , 2022, , 69-108.		0
1188	Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World Journal of Clinical Oncology, 2021, 12, 1009-1022.	0.9	4
1189	Clinical and genomic features of SPOP mutant prostate cancer. Prostate, 2022, 82, 260-268.	1.2	20
1190	Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis. Acta Clinica Belgica, 2022, 77, 897-905.	0.5	2
1191	Treatment of metastatic hormone-sensitive prostate cancer. Trends in Urology & Men's Health, 2021, 12, 7-10.	0.2	0
1192	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 778858.	1.3	7
1193	Disparities in germline testing among racial minorities with prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 403-410.	2.0	22

#	ARTICLE	IF	CITATIONS
1194	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	0.8	40
1195	Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study. <i>BMJ Open</i> , 2021, 11, e048996.	0.8	2
1196	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12095.	1.8	13
1197	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	1.3	12
1198	A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer. <i>BMC Cancer</i> , 2021, 21, 1281.	1.1	3
1199	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. <i>Value in Health</i> , 2022, 25, 796-802.	0.1	6
1200	Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110518.	1.4	3
1201	Landscape of Immunotherapy in Genitourinary Malignancies. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 143-192.	0.8	2
1202	Genetic Analysis Reveals the Prognostic Significance of the DNA Mismatch Repair Gene MSH2 in Advanced Prostate Cancer. <i>Cancers</i> , 2022, 14, 223.	1.7	5
1203	Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. <i>Oncologist</i> , 2022, 27, 220-227.	1.9	5
1204	Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE Study. <i>European Urology Open Science</i> , 2022, 36, 51-58.	0.2	2
1205	The prostate cancer landscape in Europe: Current challenges, future opportunities. <i>Cancer Letters</i> , 2022, 526, 304-310.	3.2	16
1206	Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study. <i>European Journal of Cancer</i> , 2022, 162, 56-64.	1.3	14
1207	A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer. <i>European Urology Open Science</i> , 2022, 36, 9-18.	0.2	6
1208	Metastatic Prostate Cancer: Treatment Options. <i>Oncology</i> , 2022, 100, 48-59.	0.9	47
1210	Presence of CD133-positive circulating tumor cells predicts worse progression-free survival in patients with metastatic castration-sensitive prostate cancer. <i>International Journal of Urology</i> , 2022, 29, 383-389.	0.5	6
1211	Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors. <i>JMA Journal</i> , 2022, 5, 83-90.	0.6	1
1213	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. <i>Prostate International</i> , 2022, 10, 21-27.	1.2	3

#	ARTICLE	IF	CITATIONS
1214	Feasibility and safety of radical prostatectomy for oligoâ€metastatic prostate cancer: the Testing Radical prostatectomy in men with prostate cancer and oligoâ€Metastases to the bone (TRoMbone) trial. <i>BJU International</i> , 2022, 130, 43-53.	1.3	26
1215	Rational Second-Generation Antiandrogen Use in Prostate Cancer. <i>Oncologist</i> , 0, , .	1.9	10
1216	Macrophages as a Therapeutic Target in Metastatic Prostate Cancer: A Way to Overcome Immunotherapy Resistance?. <i>Cancers</i> , 2022, 14, 440.	1.7	20
1218	Chimeric Antigen Receptor T-Cell Therapy in Metastatic Castrate-Resistant Prostate Cancer. <i>Cancers</i> , 2022, 14, 503.	1.7	21
1219	Sequencing of Systemic Therapies in the Management of Advanced Prostate Cancer in India: a Delphi-Based Consensus. <i>Oncology and Therapy</i> , 2022, 10, 143-165.	1.0	1
1220	Approach to the Treatment of Metastatic Castration-Sensitive Prostate Carcinoma: A Single Center Experience. <i>Journal of Basic and Clinical Health Sciences</i> , 2022, 6, 296-304.	0.2	1
1221	Distribution and Effects of Estrogen Receptors in Prostate Cancer: Associated Molecular Mechanisms. <i>Frontiers in Endocrinology</i> , 2021, 12, 811578.	1.5	11
1222	High IL-23+ cells infiltration correlates with worse clinical outcomes and abiraterone effectiveness in patients with prostate cancer. <i>Asian Journal of Andrology</i> , 2022, 24, 147.	0.8	5
1223	Platinum-Based Neoadjuvant Chemotherapy Before Radical Prostatectomy for Locally Advanced Prostate Cancer With Homologous Recombination Deficiency: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 777318.	1.3	2
1224	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	6.3	173
1225	Radiotherapy for Advanced Prostate Cancer. , 2022, , 197-213.		1
1226	Representation and Outcomes of Older Adults in Practice-Changing Oncology Trials in the Era of Novel Therapies: A Guideline Appraisal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 37-44.	2.3	7
1227	Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 64.e1-64.e8.	0.8	8
1228	Clinical outcomes of dose-escalated hypofractionated external beam radiotherapy (5 Gy x 5 fractions) for spine metastasis. <i>Advances in Radiation Oncology</i> , 2022, 7, 100906.	0.6	1
1229	Administering Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer 1â€6 Days Compared to More Than 14 Days after the Start of LHRH Agonist Is Associated with Better Clinical Outcomes Due to Androgen Flare. <i>Cancers</i> , 2022, 14, 864.	1.7	4
1230	Combinatorial radiation therapy for prostate cancer with seminal vesicle invasion. <i>Onkourologiya</i> , 2022, 17, 94-99.	0.1	0
1231	Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/âˆ™ Docetaxel. <i>Cancers</i> , 2022, 14, 815.	1.7	3
1232	Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer. <i>JAMA Oncology</i> , 2022, , .	3.4	0

#	ARTICLE	IF	CITATIONS
1233	Combination therapy in metastatic hormone-sensitive prostate cancer: is three a crowd?. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210868.	1.4	7
1234	New TRPM8 Blockers Exert Anticancer Activity Over Castration-Resistant Prostate Cancer Models. SSRN Electronic Journal, 0, , .	0.4	0
1235	Endokrines System und Immunmodulation. , 2022, , 799-885.		0
1236	The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.. PLoS ONE, 2022, 17, e0259672.	1.1	2
1238	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. BMC Cancer, 2022, 22, 177.	1.1	2
1239	Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized Therapy. Cancers, 2022, 14, 892.	1.7	7
1240	Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing. Medical Sciences (Basel, Switzerland), 2022, 10, 15.	1.3	13
1241	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. Prostate, 2022, 82, 676-686.	1.2	4
1242	Comparison of 2-Weekly and 3-Weekly Dosing of Docetaxel in Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 2022, , .	0.9	2
1243	Management of prostate cancer in older patients. Japanese Journal of Clinical Oncology, 2022, 52, 513-525.	0.6	5
1244	Stereotactic Body Radiation Therapy in Patients with Oligometastatic Disease: Clinical State of the Art and Perspectives. Cancers, 2022, 14, 1152.	1.7	10
1245	Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting. Scandinavian Journal of Urology, 2022, 56, 114-118.	0.6	2
1246	Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy. Cancers, 2022, 14, 967.	1.7	5
1247	Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer. Biomolecules, 2022, 12, 309.	1.8	14
1248	Prostate Cancer and Sleep Disorders: A Systematic Review. Cancers, 2022, 14, 1784.	1.7	5
1249	Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw. Current Oncology, 2022, 29, 1709-1722.	0.9	7
1250	Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. Prostate, 2022, 82, 858-866.	1.2	10
1251	Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy. Anticancer Research, 2022, 42, 1911-1918.	0.5	8

#	ARTICLE	IF	CITATIONS
1252	Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events. <i>Anticancer Research</i> , 2022, 42, 2023-2028.	0.5	7
1254	Long-Term Outcomes of a Phase I Trial of Weekly Docetaxel, Total Androgen Blockade, and Image Guided Intensity Modulated Radiation Therapy for Localized High-Risk Prostate Adenocarcinoma. <i>Advances in Radiation Oncology</i> , 2022, 7, 100935.	0.6	1
1255	Characterization of long-term survivors of primary metastatic prostate cancer patients in Norway. <i>Acta OncolÃ³gica</i> , 2022, 61, 615-618.	0.8	0
1256	Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers. <i>Research and Reports in Urology</i> , 2022, Volume 14, 87-108.	0.6	13
1257	Development of a bayesian toxo-equivalence model between docetaxel and paclitaxel. <i>IScience</i> , 2022, 25, 104045.	1.9	1
1258	Targeting the androgen receptor signaling pathway in advanced prostate cancer. <i>American Journal of Health-System Pharmacy</i> , 2022, 79, 1224-1235.	0.5	5
1259	Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2Ã—2 factorial design. <i>Lancet, The</i> , 2022, 399, 1695-1707.	6.3	261
1260	First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer Registry. <i>Tumori</i> , 2023, 109, 224-232.	0.6	3
1261	Efficacy and safety exposureâ€”response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 629-641.	1.1	6
1262	Triplet therapy for prostate cancer. <i>Lancet, The</i> , 2022, 399, 1670-1671.	6.3	1
1263	Current standards and practice changing studies in genitourinary (GU) cancersâ€”a review of studies in localized/early GU cancers. <i>ESMO Open</i> , 2022, 7, 100432.	2.0	0
1264	Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. <i>World Journal of Clinical Cases</i> , 2022, 10, 3461-3471.	0.3	2
1265	The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer. <i>Anticancer Research</i> , 2022, 42, 165-172.	0.5	4
1266	Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 8.	1.1	10
1267	Efficacy of enzalutamide in patients with metastatic hormone-sensitive and castration-refractory prostate cancer: authorsâ€™ experience. <i>Meditinskiy Sovet</i> , 2021, , 130-136.	0.1	0
1268	Targeting the Intrinsic Apoptosis Pathway: A Window of Opportunity for Prostate Cancer. <i>Cancers</i> , 2022, 14, 51.	1.7	12
1269	Assessment of Health-Related Quality of Life in Patients with Advanced Prostate Cancerâ€”Current State and Future Perspectives. <i>Cancers</i> , 2022, 14, 147.	1.7	2
1270	Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 769068.	1.3	5

#	ARTICLE	IF	CITATIONS
1271	Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. <i>Cancers</i> , 2022, 14, 166.	1.7	0
1272	Systemic Triple Therapy in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Ready for Prime Time or Still to Be Explored?. <i>Cancers</i> , 2022, 14, 8.	1.7	12
1273	Multigene Profiling of Circulating Tumor Cells (CTCs) for Prognostic Assessment in Treatment-Naïve Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>International Journal of Molecular Sciences</i> , 2022, 23, 4.	1.8	6
1274	Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. <i>Neoplasia</i> , 2021, 23, 1261-1274.	2.3	4
1275	Kastrasyon Duyarlı Metastatik Prostat Kanserinde Ğki Prognostik BelirteĖ: ALP ve Gleason Skoru. <i>Van SaĖlık Bilimleri Dergisi</i> , 0, , .	0.6	0
1276	GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical) <i>TJ ETQq1 1 0.784314 rgBT /Overl</i>	0.7	14
1277	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	2.3	29
1278	Androgen Flare after LHRH Initiation Is the Side Effect That Makes Most of the Beneficial Effect When It Coincides with Radiation Therapy for Prostate Cancer. <i>Cancers</i> , 2022, 14, 1959.	1.7	2
1279	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. <i>European Urology</i> , 2022, 82, 115-141.	0.9	51
1280	Where Do We Stand in the Management of Oligometastatic Prostate Cancer? A Comprehensive Review. <i>Cancers</i> , 2022, 14, 2017.	1.7	6
1281	The emerging role of cross-resistance between taxanes and AR-targeting therapy in metastatic prostate cancer. <i>Journal of Clinical Urology</i> , 2024, 17, 182-189.	0.1	0
1282	Head-To-Head Comparison of ⁶⁸ Ga-PSMA-11 PET/CT and ^{99m} Tc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis. <i>American Journal of Roentgenology</i> , 2022, 219, 386-395.	1.0	16
1290	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 82-96.	0.9	15
1291	Prostate cancer androgen receptor splice variant 7 biomarker study - a multicentre randomised feasibility trial of biomarker-guided personalised treatment in patients with advanced prostate cancer (the VARIANT trial) study protocol. <i>BMJ Open</i> , 2019, 9, e034708.	0.8	6
1292	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). <i>Journal of Clinical Oncology</i> , 2022, 40, 3301-3309.	0.8	14
1293	WHO SHOULD RECEIVE RADIOTHERAPY IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER?. <i>Acta Clinica Croatica</i> , 2019, 58, 36-41.	0.1	0
1294	WHO SHOULD RECEIVE NOVEL HORMONAL THERAPY WITH ANDROGEN DEPRIVATION THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER?. <i>Acta Clinica Croatica</i> , 2019, 58, 69-72.	0.1	0
1295	Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate. <i>Indian Journal of Urology</i> , 2021, 37, 72.	0.2	1

#	ARTICLE	IF	CITATIONS
1297	Metastatic and Secondary Orbital Tumors. , 2022, , 5403-5417.		0
1299	Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 594-602.	0.9	1
1300	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805. <i>Prostate</i> , 2022, 82, 1176-1185.	1.2	2
1301	Patients with Positive Lymph Nodes after Radical Prostatectomy and Pelvic Lymphadenectomy—Do We Know the Proper Way of Management?. <i>Cancers</i> , 2022, 14, 2326.	1.7	2
1302	New TRPM8 blockers exert anticancer activity over castration-resistant prostate cancer models. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114435.	2.6	8
1303	Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7. <i>Cell Death Discovery</i> , 2022, 8, 241.	2.0	2
1304	The role of chemotherapy in metastatic prostate cancer. <i>Current Opinion in Urology</i> , 2022, 32, 292-301.	0.9	4
1305	Neoadjuvant Chemohormonal Therapy in Prostate Cancer Before Radical Prostatectomy: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
1307	Diagnosis and treatment of metastatic prostate cancer. , 2022, , 23-47.		0
1308	Metronomic Chemotherapy in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 2853.	1.0	6
1309	Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. <i>European Urology Oncology</i> , 2022, 5, 605-616.	2.6	29
1310	Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis. <i>World Journal of Urology</i> , 0, , .	1.2	3
1311	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 377-387.	2.6	4
1313	Clinical implications of homologous recombination repair mutations in prostate cancer. <i>Prostate</i> , 2022, 82, .	1.2	4
1314	Advanced delivery of leuprorelin acetate for the treatment of prostatic cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 703-715.	1.1	2
1315	Prostate Cancer Treatment: ¹⁷⁷ Lu-PSMA-617 Considerations, Concepts, and Limitations. <i>Journal of Nuclear Medicine</i> , 2022, 63, 823-829.	2.8	6
1316	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
1317	Changes in Characteristics of Men with Lethal Prostate Cancer During the Past 25 Years: Description of Population-based Deaths. <i>European Urology Open Science</i> , 2022, 41, 81-87.	0.2	0

#	ARTICLE	IF	CITATIONS
1318	Approach for reporting master protocol study designs on ClinicalTrials.gov: qualitative analysis. <i>BMJ</i> , 2022, 376, e067745.	3.0	1
1319	Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study. <i>Prostate</i> , 2022, 72, 1-11.	1.2	1
1322	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	40
1323	Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer. <i>BJU International</i> , 2022, 126, 1-11.	0.7	1
1324	Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. <i>Theranostics</i> , 2022, 12, 4965-4979.	4.6	18
1326	Is docetaxel-free interval a predictive factor for castration-resistant prostate cancer?. <i>Actas Urológicas Españolas (English Edition)</i> , 2022, , .	0.2	0
1327	Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer. <i>Prostate</i> , 2022, 72, 1-11.	1.2	1
1328	Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Controlled Trial-Based Network Meta-Analysis. <i>Journal of Oncology</i> , 2022, 2022, 1-20.	0.6	0
1329	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 1-11.	2.0	4
1330	CAR-T Cells in the Treatment of Urologic Neoplasms: Present and Future. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	4
1331	Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer. <i>BJU International</i> , 2022, 126, .	1.3	2
1332	Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. <i>European Urology</i> , 2022, 82, 494-502.	2.6	21
1333	circCYP24A1 promotes Docetaxel resistance in prostate Cancer by Upregulating ALDH1A3. <i>Biomarker Research</i> , 2022, 10, .	2.8	8
1334	Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 133-141.	2.0	2
1335	Understanding the Current Therapeutic Landscape for Advanced Prostate Cancer (CME article). <i>International Journal of Cancer Care and Delivery</i> , 2022, 2, .	0.0	0
1336	Current status and future perspective on the management of metastatic castration-sensitive prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100606.	0.7	4
1337	The Swedish national guidelines on prostate cancer, part 2: recurrent, metastatic and castration resistant disease. <i>Scandinavian Journal of Urology</i> , 2022, 56, 278-284.	0.6	10
1338	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with prostate cancer. <i>ESMO Open</i> , 2022, 7, 100518.	2.0	10

#	ARTICLE	IF	CITATIONS
1339	Intensification of androgen deprivation therapy in high-risk, non-metastatic prostate cancer: Lessons from STAMPEDE. <i>JNCI Cancer Spectrum</i> , 0, , .	1.4	0
1340	Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 110, 102441.	3.4	10
1341	Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	11
1342	Single-nucleotide polymorphismAssociations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel. <i>Pharmacogenomics</i> , 0, , .	0.6	0
1343	Rupture of liver metastasis in ^{high}-volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy. <i>IJU Case Reports</i> , 0, , .	0.1	0
1344	Prostate Cancer Drug Therapy: What Have Clinicians Missed During the COVID-19 Pandemic. <i>American Journal of Men's Health</i> , 2022, 16, 155798832211155.	0.7	1
1345	Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety. <i>JNCI Cancer Spectrum</i> , 2022, 6, .	1.4	4
1346	Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer. <i>World Journal of Urology</i> , 2023, 41, 2021-2031.	1.2	3
1347	A Systematic Review and a Meta-analysis of Randomized Controlled Trialsâ€™ Control Groups in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). <i>Current Oncology Reports</i> , 2022, 24, 1633-1644.	1.8	4
1348	Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	1
1349	Adenosquamous Carcinoma of Skeneâ€™s Gland: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1350	Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment. <i>Annals of Nuclear Medicine</i> , 2022, 36, 964-975.	1.2	3
1351	Analysis of adaptive platform trials using a network approach. <i>Clinical Trials</i> , 2022, 19, 479-489.	0.7	5
1353	Advancements in the treatment of metastatic hormone-sensitive prostate cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1354	Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 82, 584-598.	0.9	44
1355	Combining androgen deprivation and radiation therapy in the treatment of localised prostate cancer: Summary of level 1 evidence and current gaps in knowledge. <i>Clinical and Translational Radiation Oncology</i> , 2022, 37, 1-11.	0.9	0
1356	The clinical consequences of routine ⁶⁸Ga-PSMA-11 PET/CT in patients with newly diagnosed prostate cancer, ISUP grade 5 and no metastases based on standard imaging â€” preliminary results. <i>Scandinavian Journal of Urology</i> , 2022, 56, 353-358.	0.6	1
1357	Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancerâ€™ exploratory analysis of LATITUDE study. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 96-104.	2.0	2

#	ARTICLE	IF	CITATIONS
1358	Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 1249-1260.	5.1	18
1359	Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. <i>ESMO Open</i> , 2022, 7, 100575.	2.0	10
1360	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1-55.		0
1361	Comparison of Doublet and Triplet Therapies for Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Network Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1362	Diagnostic Applications of Nuclear Medicine: Prostatic Cancer. , 2022, , 1023-1075.		0
1364	Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer. <i>World Journal of Urology</i> , 2023, 41, 2063-2068.	1.2	2
1366	Ductal prostate cancer: Clinical features and outcomes from a multicenter retrospective analysis and overview of the current literature. <i>Current Urology</i> , 2022, 16, 218-226.	0.4	3
1367	Insights from DOCK2 in cell function and pathophysiology. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	8
1368	Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel. <i>Cancers</i> , 2022, 14, 4757.	1.7	2
1369	Accumulation of copy number alterations and clinical progression across advanced prostate cancer. <i>Genome Medicine</i> , 2022, 14, .	3.6	9
1370	Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. <i>Research and Reports in Urology</i> , 0, Volume 14, 339-350.	0.6	8
1371	Clinical predictive value of naïve and memory T cells in advanced NSCLC. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1372	Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. <i>NIHR Open Research</i> , 0, 2, 49.	0.0	0
1373	The treatment of metastatic, hormone-sensitive prostatic carcinoma. <i>Deutsches A&#x0308;rztblatt International</i> , 0, , .	0.6	2
1374	Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2023, 9, 96-105.	1.6	26
1375	External Beam Radiation Therapy With or Without Brachytherapy Boost in Men With Very-High-Risk Prostate Cancer: A Large Multicenter International Consortium Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 645-653.	0.4	3
1376	Do disease status and race affect the efficacy of zoledronic acid in patients with prostate cancer? A systematic review and meta-analysis of randomized control trials. <i>PLoS ONE</i> , 2022, 17, e0275176.	1.1	0
1377	UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naïve and castration-sensitive prostate cancer. <i>Canadian Urological Association Journal</i> , 2022, 16, .	0.3	0

#	ARTICLE	IF	CITATIONS
1378	Chromosomal Instability in Cell-free DNA as a Prognostic Biomarker of Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy. <i>European Urology Focus</i> , 2023, 9, 89-95.	1.6	1
1379	Application of Internet-based multidisciplinary management in patients with genitourinary cancers in China: A brief introduction to a new model of healthcare service for cancer survivors during COVID-19 pandemic. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1382	Second generation anti-androgens and androgen deprivation therapy with radiation therapy in the definitive management of high-risk prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 0, , .	2.0	1
1383	Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer. <i>European Urology Open Science</i> , 2022, 45, 68-75.	0.2	2
1384	Treatment Intensification for Low-risk Metastatic Hormone-sensitive Prostate Cancer: The Time Is Now. <i>European Urology Open Science</i> , 2022, 45, 41-43.	0.2	2
1385	PEARLS â€œ A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMAâ€œvid pelvic and/or para-aortic lymph nodes at presentation. <i>Clinical and Translational Radiation Oncology</i> , 2022, 37, 130-136.	0.9	2
1386	How Genome-Wide Analysis Contributes to Personalized Treatment in Cancer, Including Gynecologic Cancer?. <i>Comprehensive Gynecology and Obstetrics</i> , 2022, , 115-132.	0.0	0
1387	Outcome of docetaxel in treatment of metastatic hormone-sensitive prostate cancer and correlation with hemoglobin, albumin, lymphocyte and platelets score. <i>Wspolczesna Onkologia</i> , 2022, 26, 196-203.	0.7	0
1388	Dosimetric Evaluation of the Inter-Fraction Motion of Organs at Risk in SBRT for Nodal Oligometastatic Prostate Cancer. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 10949.	1.3	0
1390	UnCHAARTED territory: The role of docetaxel rechallenge following chemohormonal therapy for metastatic castration-sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 539.e17-539.e22.	0.8	1
1391	S-nitrosylation of CSF1 receptor increases the efficacy of CSF1R blockage against prostate cancer. <i>Cell Death and Disease</i> , 2022, 13, .	2.7	4
1392	Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone. <i>PLoS ONE</i> , 2022, 17, e0276081.	1.1	1
1393	Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 1163-1175.	1.1	6
1394	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Diagnosis and management of localised disease. <i>Progres En Urologie</i> , 2022, 32, 1275-1372.	0.3	15
1395	The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2023, 21, 415.e1-415.e8.	0.9	0
1396	French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance. <i>Progres En Urologie</i> , 2022, 32, 1373-1419.	0.3	5
1397	Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients. <i>World Journal of Urology</i> , 2022, 40, 2939-2946.	1.2	1
1398	Effect of the Surfactant Charge on the Characteristics and Anticancer Effects of Docetaxel-loaded Poloxamer Polymeric Micelles. <i>Pharmaceutical Nanotechnology</i> , 2023, 11, 167-179.	0.6	1

#	ARTICLE	IF	CITATIONS
1399	Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2023, 41, 233-239.	0.8	7
1400	Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate. <i>European Urology Open Science</i> , 2023, 47, 1-2.	0.2	0
1401	Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy. <i>Cancer Letters</i> , 2023, 554, 216011.	3.2	7
1402	Prostatakarzinom: palliative Therapie. <i>Springer Reference Medizin</i> , 2022, , 1-24.	0.0	0
1403	Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer?. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 120.	0.1	0
1404	Stereotactic ablative radiotherapy for oligometastatic prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2022, 27, 778-786.	0.3	0
1405	Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis. <i>Current Oncology</i> , 2022, 29, 9511-9524.	0.9	3
1406	Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. <i>European Urology</i> , 2023, 83, 267-293.	0.9	39
1407	Investigating PSMA differential expression in canine uroepithelial carcinomas to aid disease-based stratification and guide therapeutic selection. <i>BMC Veterinary Research</i> , 2022, 18, .	0.7	0
1408	Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. <i>Cancers</i> , 2022, 14, 6194.	1.7	6
1409	Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change. <i>Systematic Reviews</i> , 2022, 11, .	2.5	0
1410	Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?. <i>Nature Reviews Urology</i> , 2023, 20, 116-123.	1.9	9
1411	The role of carboplatin in combination with paclitaxel in patients with castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 4183-4192.	1.1	1
1412	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. <i>BMC Cancer</i> , 2022, 22, .	1.1	4
1413	Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapy. <i>Journal of Geriatric Oncology</i> , 2023, 14, 101411.	0.5	2
1414	Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancer. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	0
1415	Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study. <i>World Journal of Urology</i> , 2023, 41, 67-75.	1.2	1
1416	Spinal Metastases and the Evolving Role of Molecular Targeted Therapy, Chemotherapy, and Immunotherapy. <i>Neurospine</i> , 2022, 19, 978-993.	1.1	3

#	ARTICLE	IF	CITATIONS
1417	Genetic variations predicting progression with docetaxel and novel androgen receptor pathway inhibitors. <i>Cancer Science</i> , 2023, 114, 1625-1634.	1.7	2
1418	The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	6
1419	A retrospective study to evaluate the effect of preoperative hormonal therapy on continence recovery. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1420	Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice. <i>Yonsei Medical Journal</i> , 2023, 64, 86.	0.9	3
1421	Physical activity and dietary considerations for prostate cancer patients: future research directions. <i>Proceedings of the Nutrition Society</i> , 2023, 82, 298-304.	0.4	2
1422	Par14 interacts with the androgen receptor, augmenting both its transcriptional activity and prostate cancer proliferation. <i>Cancer Medicine</i> , 0, , .	1.3	2
1424	Elucidating molecular and cellular targets and the antiprostate cancer potentials of promising phytochemicals: a review. <i>Anti-Cancer Drugs</i> , 0, Publish Ahead of Print, .	0.7	0
1425	Prostate and metastasis-directed focal therapy in prostate cancer: hype or hope?. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 163-176.	1.1	0
1426	Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review. <i>World Journal of Men's Health</i> , 2023, 41, 769.	1.7	10
1427	Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. <i>Annals of Oncology</i> , 2023, 34, 557-563.	0.6	10
1428	Online error rate control for platform trials. <i>Statistics in Medicine</i> , 2023, 42, 2475-2495.	0.8	4
1429	Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. <i>European Journal of Cancer</i> , 2023, 185, 178-215.	1.3	26
1430	Role of apalutamide in the treatment landscape for patients with advanced prostate cancer: an expert opinion statement of European clinical practice. <i>Irish Journal of Medical Science</i> , 0, , .	0.8	1
1431	A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer. <i>Actas Urológicas Españolas (English Edition)</i> , 2023, 47, 111-126.	0.2	0
1432	A systematic review and meta-analysis on overall survival, failure-free survival and safety outcomes in patients with metastatic hormone-sensitive prostate cancer treated with new anti-androgens.. <i>Anti-Cancer Drugs</i> , 2023, 34, 405-412.	0.7	1
1433	Improving solubility of poorly water-soluble drugs by protein-based strategy: A review. <i>International Journal of Pharmaceutics</i> , 2023, 634, 122704.	2.6	14
1434	Body composition parameters were associated with response to abiraterone acetate and prognosis in patients with metastatic castration-resistant prostate cancer. <i>Cancer Medicine</i> , 2023, 12, 8251-8266.	1.3	1
1435	Utilizing mixture design response surface methodology to determine effective combinations of plant derived compounds as prostate cancer treatments. <i>Cancer Reports</i> , 2023, 6, .	0.6	2

#	ARTICLE	IF	CITATIONS
1457	Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trial. NIHR Open Research, 0, 2, 49.	0.0	0
1458	Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update. Journal of Clinical Oncology, 2023, 41, 3652-3656.	0.8	1
1459	Real-World Treatment Trends Among Patients with Metastatic Castration-Sensitive Prostate Cancer: Results from an International Study. Oncologist, 2023, 28, 780-789.	1.9	4
1460	Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study. Oncologist, 2023, 28, e737-e747.	1.9	2
1461	Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer. JAMA Oncology, 2023, 9, 825.	3.4	28
1462	Budget impact analysis of enzalutamide for the treatment of hormone-sensitive metastatic prostate cancer in Italy. Global & Regional Health Technology Assessment, 0, 10, 29-39.	0.2	0
1463	Hormonal Therapies for Patients with Advanced Prostate Cancer. European Medical Journal (Chelmsford, England), 0, , 39-51.	3.0	0
1464	Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14). Acta Oncologica, 2023, 62, 372-380.	0.8	2
1465	Combination therapy for high-volume versus low-volume metastatic hormone-sensitive prostate cancer: A systematic review and network meta-analysis. Frontiers in Pharmacology, 0, 14, .	1.6	2
1467	Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)â€”A Potential New Standard of Care. Current Oncology, 2023, 30, 4365-4378.	0.9	5
1497	Prostatakarzinom: palliative Therapie. Springer Reference Medizin, 2023, , 1593-1616.	0.0	0
1521	Metastatic Prostate Cancer. , 2023, , 241-255.		0
1525	Die Rolle der Strahlentherapie beim metastasierten hormonsensitiven Prostatakarzinom. , 2023, , 23-37.		0
1530	Overcoming resistance in prostate cancer with targeted and small molecule-based therapies. , 2024, , 255-287.		0
1554	The yin and yang of chromosomal instability in prostate cancer. Nature Reviews Urology, 0, , .	1.9	0
1570	Diagnostic, Prognostic and Theranostic Potential of miRNAs in Prostate Cancer. , 2024, , 147-168.		0